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Abstract
TREM2 variants have been identified as risk factors for Alzheimer’s disease (AD) and other neurodegenerative
diseases (NDDs). Because TREM2 encodes a receptor exclusively expressed on immune cells, identification of these
variants conclusively demonstrates that the immune response can play an active role in the pathogenesis of NDDs.
These TREM2 variants also confer the highest risk for developing Alzheimer’s disease of any risk factor identified in
nearly two decades, suggesting that understanding more about TREM2 function could provide key insights into NDD
pathology and provide avenues for novel immune-related NDD biomarkers and therapeutics. The expression, signaling
and function of TREM2 in NDDs have been extensively investigated in an effort to understand the role of immune
function in disease pathogenesis and progression. We provide a comprehensive review of our current understanding
of TREM2 biology, including new insights into the regulation of TREM2 expression, and TREM2 signaling and function
across NDDs. While many open questions remain, the current body of literature provides clarity on several issues. While
it is still often cited that TREM2 expression is decreased by pro-inflammatory stimuli, it is now clear that this is true in
vitro, but inflammatory stimuli in vivo almost universally increase TREM2 expression. Likewise, while TREM2 function is
classically described as promoting an anti-inflammatory phenotype, more than half of published studies demonstrate a
pro-inflammatory role for TREM2, suggesting that its role in inflammation is much more complex. Finally, these
components of TREM2 biology are applied to a discussion of how TREM2 impacts NDD pathologies and the latest
assessment of how these findings might be applied to immune-directed clinical biomarkers and therapeutics.
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Background
Human genetic studies have provided crucial insight into
neurodegenerative disease (NDD) pathogenesis. Alzheimer’s
disease (AD) is a prime example of how advances in genetic
technology have facilitated the evolution of our under-
standing of the etiology of NDDs. Early studies using
genetic linkage approaches identified familial mutations
in proteins related to amyloid beta production, amyloid
precursor protein (APP), presenilin 1 (PSEN1) and PSEN2,
as well as the late onset AD (LOAD) risk variant apolipo-
protein E4 (APOE4) [1]. These studies provided important
insight into amyloid as a critical factor in AD pathogenesis
and prompted application of molecular approaches and
animal models to understand the disease. Since 2007 [2],
case-control genome wide association studies (GWAS)
have identified many novel AD-associated genetic variants
[3]. Though many of these individually confer only
modestly elevated risk for developing AD, collectively
these studies provide broad insight into the pathways
and processes involved in LOAD. Many identified
genetic linkages are implicated in modulating immune
function [4], demonstrating an important role for the
immune response in AD.
More recently, next generation sequencing technologies
have made possible the identification of rare variants,
some of which may confer higher disease risk and there-
fore can provide important insight into genes with strong
biological roles in disease [1]. The application of whole
exome sequencing [5] and GWAS with imputation based
on predicted genetic associations [6] to AD led to the
identification of relatively rare variants in the gene trig-
gering receptor expressed on myeloid cells 2 (TREM2)
that are associated with a high risk for developing AD.
Heterozygous TREM2 variants confer similar risk for
AD as one copy of APOE4. Significantly, the AD-
associated TREM2 variants are largely coding variants,
* Correspondence: glandret@iu.edu
1Department of Neurosciences, Case Western Reserve University, School of
Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA
2Stark Neurosciences Research Institute, Indiana University School of
Medicine, 320 W 15th Street, Indianapolis, IN 46202, USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jay et al. Molecular Neurodegeneration  (2017) 12:56 
DOI 10.1186/s13024-017-0197-5
in contrast to most of the single nucleotide polymor-
phisms (SNPs) identified in GWAS [7], making it
more straightforward to translate into in vitro and in
vivo models and perhaps also into therapeutics [8].
TREM2 variants have now also been linked to other
NDDs, suggesting that TREM2 is critically involved in
shared disease mechanisms.
The excitement in the field following identification of
these AD-associated TREM2 variants was also driven by
its implications, providing a clear link between the
innate immune system and NDD pathogenesis. While it
has long been known that immune cell function is dys-
regulated in AD and other NDDs, it was not clear
whether this actively contributed to disease pathogenesis
and progression or was just a secondary response to
AD-related pathology. However, this debate was largely
settled in favor of the former when TREM2 variants
were found to be significantly associated with risk for
AD and other NDDs, and to form a genetic basis of
polycystic lipomembraneous osteodysplasia with sclerosing
leukoencephalopathy (PLOSL, also known as Nasu-Hakola
disease). Because TREM2 is exclusively expressed on
immune cells, these genetic associations were hailed as
providing conclusive evidence that immune dysregulation
can be a primary, causal contributor to NDD pathogenesis
[9, 10]. Thus, NDD-associated TREM2 variants provide a
new avenue to investigate the important roles that the
immune system plays in neurodegeneration [11].
In the 4 years since TREM2 variants associated with
AD risk were identified, many groups have developed
research programs aimed at understanding TREM2 gen-
etics, expression, structure, signaling, function, and its
relationship to NDD pathologies and applied these find-
ings to clinical biomarkers and therapeutics. Progress in
these areas has clarified our understanding of the biology
of the TREM2 receptor. While it was previously thought
that TREM2 expression was decreased by pro-
inflammatory stimuli and mediated anti-inflammatory
effects, it is now clear that its roles are more complex. In
vitro, inflammatory stimuli decrease TREM2 expression
but in vivo TREM2 expression is increased in inflamma-
tory contexts. More than half of studies report that
TREM2 has a pro-inflammatory effect, suggesting that
there must be cell type- and context-dependent functions
of the receptor. Recent studies have also illuminated new
aspects of TREM2 biology which necessitate a reevalua-
tion and reinterpretation of previous literature. One
example is the finding that soluble TREM2 is produced in
AD in a disease progression-dependent manner [12] and
that this soluble form of the receptor may have distinct
biological effects [13, 14]. Other fundamental aspects of
TREM2 biology are also under intense investigation,
including epigenetic and posttranslational modification of
TREM2 that affect expression and function, the ontogeny
of TREM2 expressing cells in the brain, and how non-
canonical signaling pathways may contribute to TREM2
function. This review offers a comprehensive synthesis of
these studies alongside previous TREM2 literature to
identify areas of consensus and emerging questions in the
field. This understanding will be crucial to support
informed design and interpretation of studies of TREM2
and the immune response in NDDs moving forward.
Genetics of TREM2 in NDDs
Diverse TREM2 variants are associated with NDD risk
There is great diversity in the TREM2 variants that have
been associated with NDDs, including single amino acid
substitutions, frameshift and nonsense mutations, and
changes in splice sites predicted to alter the inclusion or
exclusion of particular exons [15]. And, while most of
the TREM2 variants identified are present in the coding
sequence, there have also been disease-associated vari-
ants found in the 3’UTR [16], and upstream of the tran-
scription start site [17]. The first NDD-associated
TREM2 variants identified were W78X and W44X,
which result in premature truncation of the protein, a
variant at the consensus splice site which results in
exclusion of exon 3, and the K186N mutation, which
disrupts association of TREM2 with its obligate intracel-
lular signaling adaptor, DAP12 [18]. These all likely
result in a loss of TREM2 function, and a patient with
the E14X nonsense variant of TREM2 had no detectable
TREM2 transcript levels [19]. Subsequently, a host of
diverse TREM2 variants have been identified. Despite
their structural diversity, all of the NDD-associated
TREM2 variants identified have been suggested to con-
fer loss of function through different mechanisms. How-
ever, whether loss of function truly unifies all of these
variants is still very much an open question.
TREM2 variants are the genetic basis of PLOSL and some
familial FTD cases
TREM2 was first identified as a genetic cause of PLOSL,
also commonly known as Nasu-Hakola disease [20, 21],
which is characterized clinically by bone cysts and frac-
tures, neuropsychiatric symptoms and dementia [22].
Neuropathologically, PLOSL patients have axonal degen-
eration and white matter loss, as well as cortical atrophy
[23, 24]. This is accompanied by an inflammatory
response consisting of increased microglial density and
activation and astrocytosis [25]. These neurological man-
ifestations can also occur in the absence of fractures [26]
or bone cysts [27]. Paloneva and colleagues [18] were
the first to link TREM2 variants with PLOSL, and since
then, many studies have identified homozygous TREM2
variants that form the genetic basis of PLOSL [28–33].
Studies in families with frontotemporal dementia
(FTD) [34] or frontotemporal lobar dementia (FTLD)
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found that PLOSL-associated TREM2 variants T66 M
[35, 36], W198X [37], Q33X and Y38C [36] in either
homozygosity or heterozygosity could also cause FTD
[35–37] (Fig. 1). Case-control studies were then
performed to assess whether TREM2 variants might
increase risk for FTD in the general population. Initial
studies suggested that there was a positive association
between TREM2 variants as a whole and risk of FTD
[16, 38] with a significant association found between
FTD risk and individual TREM2 variants including
T96K and L211P [39] and R47H [40]. Others failed
to replicate this association with TREM2 variants and
FTD or FTLD [34, 39, 41, 42]. However, an associ-
ation between TREM2 variants and specific endophe-
notypes of FTD, including reduced white matter
volume, seizures and motor symptoms has been re-
ported [43]. Together, it is not clear whether TREM2
variants increase risk for FTD outside of specific fa-
milial cases, but they may influence specific clinical
manifestations of the disease.
Fig. 1 Diverse TREM2 variants are associated with NDDs. Genetic variants in the TREM2 gene (shown above) result in diverse changes in the
protein structure (shown below). These variants occur in almost every exon (black boxes) and impact known protein motifs (sequences highlighted
in blue) and flank many sites of known protein modifications (amino acid number and type of modification detailed inside black boxes). TREM2
variants have been found to be significantly associated with many NDDs, including AD (variants shown in yellow), FTD or FTLD (pink), PD (purple)
and PLOSL (red). The table shows genetic variants that have been found to be significantly associated with disease risk, with supporting
references shown in dark green and references that provide strong counterevidence shown in red. References shown in light green did find a
significant association between the TREM2 variant and disease risk, but only in one or multiple populations they examined or only after inclusion
of previously published literature into metastudy analyses. While these variants have been significantly associated with disease risk, many more studies
find suggestive but not significant associations between additional TREM2 variants and NDD risk which are not represented here [5, 6, 16, 18, 26, 28,
30, 31, 35–37, 39–42, 45–47, 49–52, 54, 55, 57, 58, 60, 64, 65, 67, 70, 82, 83, 88, 131, 323–325]
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TREM2 variants are associated with risk for AD
It was investigated whether TREM2 variants could also
confer risk for Alzheimer’s disease. While it was first
suggested that PLOSL-associated genes might confer
risk for AD in 1983 [44], a small, case-control study in
2007 failed to demonstrate a significant association with
AD risk [29]. However, larger studies in 2013 found that
heterozygous expression of the TREM2 R47H [5, 6] and
D87N variants [5] were significantly associated with AD
risk. The association of TREM2 variants with AD has
been extensively replicated [15, 16, 45–48] and the
R47H variant [16, 37, 41, 42, 49–56] validated in
neuropathologically-confirmed cases [57]. Other variants
have also been consistently shown to confer AD risk,
including D87N [5, 15], R62H [51, 56], L211P and
T96K, and H157Y [51, 58] (Fig. 1). While rare, individ-
uals with AD homozygous for the R47H [41, 50, 59] and
L211P [41] variants have also been identified.
Studies examining the association of TREM2 variants
with particular AD endophenotypes yielded somewhat
inconsistent results, likely due to the small sample size
of patients with these TREM2 variants. Some found that
R47H TREM2 variant carriers had a decreased [41] or a
trend toward decrease [54] in the age of AD onset,
though others found no significant association [49, 60].
Additionally, some found that disease progression was
accelerated in R47H carriers [60, 61], though this was
not observed in all studies [41]. Other variants were also
found to increase [62] or decrease [17] the rate of AD
progression. Despite possible differences in AD onset or
progression, the clinical presentation of AD in R47H
carriers is similar to non-carriers [41, 49], though there
may be a higher incidence of some endophenotypes
including seizures and motor symptoms [63].
TREM2 variants have been investigated as risk factors for
other NDDs
TREM2 variants have also been assessed as potential risk
factors for other neurodegenerative diseases, though the
findings in these other disease contexts are less defini-
tive. In amyotrophic lateral sclerosis (ALS), one study
found a significant association of the R47H variant and
ALS risk, as well as an inverse correlation between
TREM2 levels in the spinal cord and survival in ALS
patients [64], though this was not replicated by others
[40]. The TREM2 R47H variant has also been reported
to be associated with increased risk of Parkinson’s
disease [39] by some [40, 65, 66] but not all studies
[6, 42, 67]. In order to understand these differences,
Lill and colleagues [42] divided their groups by ethnicity
and found that the odds ratio of the R47H variant was
significantly higher in their Northern European population
compared to non-Northern Europeans. Others identified
another Parkinson’s disease (PD)-associated SNP 5 kb
upstream of TREM2 [66], though its effect on TREM2
expression is not known. The TREM2 R47H variant has
also been investigated as a risk factor for posterior cortical
atrophy [68], multiple system atrophy [69], essential
tremor [70], multiple sclerosis [71] and Creutzfeldt-Jakob
disease (CJD) [41], though these studies were not conclu-
sive. One family has been identified in which a mutation
in TREM2 is thought to result in progressive non-fluent
aphasia [72], though other cases will be necessary to con-
firm this association. So far, evidence suggests that TREM2
variants are not significantly associated with dementia with
Lewy Bodies [73], ischemic stroke [40] or progressive
supranuclear palsy [40]. Because many of these diseases
share overlapping clinical features with AD and FTD, it
will be important to validate any associations of TREM2
with other NDDs in neuropathologically confirmed cases.
Overall, the association of TREM2 variants with these
other NDDs is less clear, and future studies with large
sample sizes in diverse but well-matched populations will
be required to definitively establish whether TREM2 vari-
ants confer risk for NDDs other than PLOSL, FTD and
AD. Importantly, the association of TREM2 variants with
multiple NDDs suggests it may underlie common disease
mechanisms. TREM2 dysfunction may provide insight into
mechanistic links among these diseases.
The epidemiology of TREM2 variants
Epidemiologically, the prevalence of TREM2 variants
differs greatly among individuals from different genetic
backgrounds [74]. In Caucasian populations, the minor al-
lele frequency (MAF) of the R47H TREM2 variant ranges
from 0.12–0.26% in the United States, to up to 2% in some
specific British populations [5, 6, 59]. While the R47H
variant is virtually absent in East Asian individuals,
[56, 69, 75–81] nine other TREM2 variants were
present in East Asian populations and collectively associ-
ated with NDD risk [82]. Similarly, the MAF of the R47H
and R62H variants are much lower in African Americans
compared to European American populations [83, 84].
However, exonic sequencing of TREM2 revealed variants
that had much higher MAFs in the African American
population compared to European Americans, and some
of these variants were significantly associated with AD risk
in that population [83]. Because of the small MAFs, it is
not clear whether the effect sizes of these variants differ
among different ethnic groups as well. The low MAFs and
diversity in the frequency of TREM2 variants across popu-
lations necessitates that studies have large study popula-
tions and be well-matched for ethnicity. It will also be
important to take advantage of the identification of these
TREM2 variants across diverse populations to gain a full
understanding of how TREM2 variants confer AD risk
and how they might interact with other genetic differences
among individuals from distinct genetic backgrounds.
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The relationship between TREM2 and other NDD genetic
risk factors
Several groups have examined the relationship between
TREM2 and other NDD risk factors. Variants in Siglec-3
(CD33) are significantly associated with AD risk and
CD33 levels on human blood monocytes were found to
inversely correlate with surface TREM2 levels [85]. The
AD-associated CD33 allele increased its surface expres-
sion, effectively decreasing TREM2 signaling. Another
AD-associated gene, Membrane-spanning 4-domain
family A (MS4A), was found to be co-enriched with
TREM2 in the human brain and is substantially upregu-
lated in monocytes derived from patients with PLOSL-
associated TREM2 variants [86]. An AD-associated SNP
in MS4A correlated with altered soluble TREM2
(sTREM2) levels in cerebrospinal fluid (CSF), suggesting
that MS4A may also regulate TREM2 expression or pro-
cessing [86]. TREM2 levels are also increased in AD
mouse models lacking PGRN expression, which models
lower PGRN expression observed with an AD and
FTLD-associated PGRN genetic variant [87].
Components of the TREM2 signaling pathway have
also been associated with NDDs, including its intracellu-
lar signaling adaptor DNAX activation protein of 12 kDa
(DAP12, also termed TYROBP). DAP12 and TREM2
variants produce virtually indistinguishable phenotypes
in PLOSL patients [18, 30]. However, Satoh and col-
leagues [25] found that dendritic cells derived from
monocytes of PLOSL patients with TREM2 or DAP12
mutations had very different patterns of gene expression,
suggesting that they may produce the same phenotype
through different molecular mechanisms. A rare DAP12
variant at the site of interaction with TREM2 also con-
fers risk for developing early onset AD [88] and DAP12
was found to play a central role in AD-related molecular
networks [89]. As its relationship to NDDs might
predict, DAP12 deficient mice also have synaptic degener-
ation and reduced myelination [90], though recent
evidence suggests that DAP12 deficiency may be neuro-
protective in an AD mouse model [91]. The precise mech-
anisms underlying these changes are not yet understood.
Variants in additional proteins associated with the
TREM2 signaling pathway, SHIP1 and colony stimulat-
ing factor 1 receptor (CSF1R), have been associated
with AD risk and leukoencephalopathy with spheroids
[92, 93]. In addition, ApoE, a putative TREM2 ligand
[94–96], is clearly established as an AD risk factor [97].
Finally, environmental risk factors for AD including
traumatic brain injury [98, 99], diabetes [100] and age
[101], all alter TREM2 expression in the brain. To-
gether, the identification of variants in genes involved
in these common immune pathways suggest that
TREM2, along with its interaction partners, together
play an important role in modifying NDD pathology.
TREM2 expression
Co-regulation of TREM2 and other members of the TREM
family
TREM2 is located on human chromosome 6 in a gene
locus containing several TREM and TREM-like genes,
such as TREM1, triggering receptor expressed on mye-
loid cells like transcript 1 (TREML1) and TREML2,
which likely originated from duplication events but now
have relatively diverse sequences [102–104]. Many of
these genes, including TREM2, are highly conserved
between humans and mice, while others are present only
in mice (TREM3 and TREML6) or humans (TREML3
and Nkp44). There may be some shared mechanisms of
gene regulation across the locus. For example, there is a
Retinoid X receptor (RXR) binding site upstream of the
entire locus that is thought to result in coordinate regu-
lation of these genes [105]. However, in some cases,
opposing regulation of these different genes has been
shown, such as between TREM2 and TREM1 [85], and
between TREM2 and TREML2 [106, 107]. It is not
known what factors contribute to these inverse correla-
tions in expression. SNPs within this locus can also
result in changes in expression of multiple TREM genes.
Variants in the TREML2 [66] and TREML4 [108] gene
have been shown to increase brain TREM2 and
TREML1 expression levels. Chan and colleagues [85]
found that AD-associated variants in TREM1 result in
reduced TREM1 expression on human monocytes and
increased TREM2 expression. Moreover, an intronic
variant in TREM1 which decreases its expression leads
to increased amyloid accumulation and cognitive decline
in AD patients [109]. However, non-AD associated vari-
ants decreased both TREM1 and TREM2 expression,
leading the authors to suggest that the ratio of TREM1
and TREM2 expression rather than the absolute changes
in expression may be important for disease. Additionally,
variants in TREML2 increase PD risk [62], and other
disease-related SNPs that alter TREML2 levels [66] associ-
ate with AD in GWAS analyses [93]. Another variant of
TREML2 was found to be protective against developing
AD [107]. An intergenic variant associated with AD risk
was shown to alter RNA levels of TREML4 [110]. These
data highlight the importance of characterizing the
expression patterns of all TREM members in an effort to
pinpoint co-regulatory mechanisms among these genes
physiologically and in the context of disease.
Regulation of TREM2 expression
TREM2 expression is highly cell-type and context spe-
cific. However, the molecular mechanisms governing this
highly specific regulation of TREM2 expression are just
beginning to be understood. While there are several pre-
dicted transcription factor binding sites in the UTR’s
and promoter region of TREM2, only a few have been
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functionally validated. PU.1, a master regulator of mye-
loid cell fate specification, is present in the TREM2
promoter [111]. The RXR agonist bexarotene was found
to enhance RXR occupancy of known binding sites [105]
upstream of TREM2 in mice, though this did not correl-
ate with increased TREM2 RNA levels [112]. However,
in AD mouse models, bexarotene did enhance gene
expression of TREM2 [112], suggesting that RXR may
effectively induce TREM2 transcription when cells are
already primed in a particular context. NKκB [113, 114],
Protein E [115], RANKL, and NFAT [116] have all been
shown to regulate TREM2 expression in different cell
types, but it is not clear whether these factors directly
regulate expression. One group has suggested that NFκB
may instead regulate TREM2 expression by increasing
levels of microRNA34a which, in reporter assays,
decreased TREM2 expression [113, 117–121]. There are
also epigenetic changes that have been shown to influ-
ence TREM2 expression. In humans, hippocampal en-
richment of 5-hydroxymethylcytosine (5hmc), a marker
of active demethylation, at the TREM2 transcription
start site and in exon 2 were found to positively correl-
ate with TREM2 mRNA levels [122]. Methylation
upstream of the TREM2 transcription start site was also
increased in AD, a context in which TREM2 levels are
also increased [123]. Additionally, methylation at the
CpG sites in intron 1 negatively correlated with TREM2
mRNA levels in human leukocytes, and methylation at
these sites was reduced in AD patients [124]. Others
have found that H3Kme2 and H3Kme3, histone modifi-
cations which typically are associated with active gene
transcription, are increased at the TREM2 locus in db/
db mouse adipose tissue [125] and in cultured dendritic
cells and macrophages during differentiation [126], con-
texts in which TREM2 mRNA levels are elevated.
Finally, there are likely post-transcriptional mecha-
nisms of regulation of TREM2 expression which contrib-
ute to differential expression in different contexts.
TREM2 mRNA stability can be dynamically regulated.
The half-life of TREM2 mRNA in cultured human per-
ipheral blood mononuclear cells went from 11.3 h to 4 h
after toll-like receptor (TLR) ligation [127]. Furthermore,
Hu and colleagues [128] found that TREM2 mRNA
expression strongly correlated with surface levels of
TREM2 protein on monocytes, but only weakly corre-
lated with protein expression on granulocytes in the
plasma. This suggests that, in addition to differential
regulation of TREM2 transcription through transcription
factors and epigenetic markers, TREM2 expression can
be further differentially controlled at the mRNA and
protein level in distinct cell types through mechanisms
which are not resolved.
How TREM2 variants affect TREM2 expression is a
topic currently under investigation. As discussed above,
some TREM2 variants are known to reduce TREM2
expression. The nonsense mutations E14X [18] and
Q33X [129] were both found to eliminate TREM2 pro-
tein expression. TREM2 RNA levels were reduced in
patients harboring the variant T66M [23] and a splice
donor mutation in intron 3 [130]. Heterozygous expres-
sion of a variant that affects TREM2 splicing in intron 1,
which is associated with early onset dementia, also
affected the expression of the common variant allele of
TREM2, reducing it by more than half [131]. It is un-
clear how these variants result in reduced TREM2 tran-
script levels, though it has been suggested that
epigenetic changes may partially account for these effects.
In contrast, the R47H variant either did not change [57]
or trended toward increasing TREM2 transcript levels
[132] in individuals with AD. Although there were no
changes found in gene methylation upstream of TREM2’s
transcription start site in R47H carriers compared to con-
trols [123], variants tend to cluster around exon 2 where
TREM2 expression was found to be correlated with 5hmc
enrichment [122]. Whether variants affect regulation of
TREM2 RNA expression at the level of epigenetics, tran-
scription factor binding, RNA stability or altering the cell
phenotype in a manner that indirectly drives alterations in
TREM2 transcription is not yet clear. At the protein
level, in transfected cell lines T66M and Y38C TREM2
variant proteins were found to be degraded by the pro-
teasome, leading to decreased protein expression [133].
In AD patients with R47H variants, there was a trend
toward decreased TREM2 protein levels in one study
[57], but a trend toward an increase in another [132]. It
will be crucial to continue collecting data from TREM2
variant carriers to gain a clearer picture of how TREM2
expression is altered by different disease-associated var-
iants. In PLOSL patients with DAP12 mutations, there
was a variable effect on DAP12 expression levels, in
some cases increasing and in others decreasing expres-
sion [23]. It may be that TREM2 variants also alter
TREM2 expression in distinct ways.
Cell types in which TREM2 is expressed
TREM2 is expressed on many cells of the myeloid
lineage, as its name suggests, including dendritic cells
[101, 126, 130, 134–136], granulocytes [128], bone mar-
row and monocyte derived macrophages [126, 130, 135,
137, 138], and tissue macrophages like splenocytes [139],
Kuppfer cells [140], alveolar macrophages [141, 142],
and osteoclasts [19, 116, 143] (Fig. 2). TREM2 is not
reported to be expressed on lymphocytes [128]. Its expres-
sion on circulating monocytes remains controversial.
Initially it was thought that TREM2 was only expressed
after differentiation of monocytes into macrophages [130],
and others have provided further data to support a lack of
TREM2 expression or expression on only a small subset
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of monocytes in humans [101, 126, 135, 144] and mice
[145]. However, others have detected TREM2 expression
in whole blood [124, 146–148] and specifically on human
[85, 128] and mouse [149] monocytes. These disparate
findings may be due to differences in sensitivity of detec-
tion or other technical factors, but it will be important to
resolve moving forward.
It is clear that TREM2 is expressed in the brain and
most evidence documents that TREM2 is expressed
exclusively within the brain by microglia. All published
studies to date find that primary cultured microglia
express TREM2 [139, 150–153]. In vivo, most studies
detect TREM2 expression in mouse microglia [11, 101,
152–157], though some find that it is expressed by only
a subset of these cells [114, 158–161] and others could
detect TREM2 RNA but not protein expression in
mouse microglia [162]. Furthermore, studies demon-
strated that when microglia are acutely depleted from
the brain through CSF1R antagonist treatment in vivo,
[163] through CD11b-HSVTK depletion in brain slices
[155], or chronically in PU.1 knockout mice [154],
TREM2 is no longer detectable in the CNS. In humans,
experimental outcomes have been more variable, with
some detecting high levels of TREM2 expression across
all microglia [156], others finding lower levels of TREM2
expression [164] and others not detecting microglial
expression of TREM2 [25]. With a few exceptions, most
evidence is in strong agreement that TREM2 is expressed,
at least under normal physiological conditions, specifically
in microglia within the CNS.
Fig. 2 TREM2 can be present as a full-length protein (shown at top) or as a soluble product. This can occur through proteolytic cleavage by ADAM10
followed by γ-secretase to produce soluble TREM2 (sTREM2), a C-terminal fragment (CTF) and an intracellular domain (ICD). TREM2 can also be alterna-
tively spliced to produce soluble isoforms. One alternative transcript has been validated in mice, while two have been validated in humans and four
others are predicted to occur [51, 132, 133, 161, 225, 228, 230, 232]
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TREM2 expression changes throughout neurodevelopment
and varies across brain regions
TREM2 expression in the CNS is also regulated through-
out development and its expression pattern varies across
different brain regions. TREM2 is first detectable in the
mouse CNS at E14 and continues to be expressed through
adulthood [154]. However, at P1, all brain myeloid cells
express TREM2 RNA, but not all of these cells still
express detectable levels by P10, which has also been sup-
ported in vitro [165]. This early elevated TREM2 expres-
sion also occurs in other organs following macrophage
infiltration during organogenesis [137]. TREM2 expres-
sion is also regulated differentially across brain regions in
humans and mice. TREM2 was found to be highly
expressed in white matter [101, 165], hippocampus
[101, 156, 165] and spinal cord [18, 156], among other
regions. While this could suggest that particular micro-
environmental niches induce TREM2 expression locally
within distinct microglial populations, it may also simply
reflect the high density of microglia in these regions [101].
Inflammatory stimuli, injury and disease drive changes in
TREM2 expression
TREM2 expression has been shown to be dramatically al-
tered in the contexts of inflammation, injury and disease. In
vitro, application of classically pro-inflammatory molecules
(TNFα [117, 136], IL1β [107, 136, 166], ROS [166, 167],
IFNγ [168], TLR agonists, including lipopolysaccharide
Fig. 3 TREM2 is expressed in many immune cells, and is localized to microglia in the CNS. TREM2 expression has been assessed in a variety of
human and mouse cell types. These data represent TREM2 expression in these cells under homeostatic conditions, though, as discussed in the
next section, TREM2 expression can change in the contexts of inflammation or pathology. References shown in green are supportive of TREM2
expression in the cell type listed while those in red did not detect TREM2 expression using the listed method of detection. References in yellow
provide evidence of expression, but at low levels or in a small percentage of cells assayed. The graph represents the cell types in which TREM2
expression has been examined at a size relative to the number of studies and methods used to detect TREM2 expression in that cell type. They
are graphed along the y-axis according to the percentage of these findings which support TREM2 expression on these cells [11, 19, 25, 26, 85, 101, 116,
126, 128, 130, 134–137, 139–143, 145, 150–160, 162, 164, 165, 216, 219, 200]
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(LPS) [106, 114, 135, 136, 167–170], CpGs [171] and other
TLR ligands [114, 127, 138, 150], mitochondrial lysates
[172] and bacteria [173]) decreased TREM2 expression,
while anti-inflammatory molecules (vasoactive intestinal
peptide [174] and IL4 [168]) increased TREM2 expression.
In contrast, in vivo, inflammation and different disease
states almost universally increase TREM2 expression. Stim-
uli that induce an inflammatory response in the lung
increase TREM2 expression in alveolar macrophages
[141, 149, 173–178]. High fat diet [100, 179] increased
inflammation and TREM2 expression in adipose tissue,
liver and brain. TREM2 is also upregulated in numer-
ous other inflammation-related contexts, including sep-
sis [180], rheumatoid arthritis [181], corneal infection
[182], macular degeneration [117], glioma [183], oral
[184], esophaegeal [185], and liver [186] cancers, following
prosthetic joint implants [187], osteoporosis [188], colonic
mucosal injury [189], colitis [190], gastrointestinal mucosi-
tis [191] and muscular sarcoidosis [192]. In the CNS,
TREM2 expression is increased in the context of trau-
matic brain injury [98, 99], stroke [160, 193], spinal
nerve transection [194], ALS [64], PD [66], prion dis-
ease [155, 195], models of demyelination [151, 159,
196–198] and following beta-amyloid (Aβ) vaccination
[199]. Only one study found reduced TREM2 expres-
sion in in vivo inflammatory contexts, following LPS in-
jection and middle cerebral artery occlusion in mice
[114]. TREM2 has also been shown in almost all cases
to positively correlate with aging, both in mouse
models [200, 201] and in humans [101]. Soluble
TREM2, a product of full-length protein cleavage or alter-
native splicing, is detectable in CSF and its levels were also
positively correlated with age [12, 86, 202, 203], though
this was not reflected in blood [204]. Taken together, these
studies largely demonstrate that, in vitro, inflammatory
stimuli decrease TREM2 expression, while in vivo, inflam-
matory stimuli predominantly increase TREM2 expres-
sion, clearly suggesting that the dogma based on early
studies that TREM2 expression is universally reduced in
inflammatory contexts is not applicable to in vivo con-
texts. Why this occurs is not clear, but may reflect differ-
ences in cell recruitment, acute versus chronic signaling,
non-cell autonomous signaling pathways, or phenotypic
changes in myeloid cells that occur when they leave their
native environment.
The most comprehensive assessment of changes in
TREM2 expression has been performed in the context
of Alzheimer’s disease. Studies in AD patient brain tissue
almost exclusively show increased TREM2 expression
[122, 132, 150, 164, 205–208], and some [124, 128, 148]
but not all [146] found this was also reflected in
increased TREM2 levels in monocytes from AD patients.
TREM2 levels in the brains of AD mouse models are
also increased. One study reports a reduction in TREM2
RNA levels before the onset of pathology in Tg2576
mice [209], though after the onset of pathology, all amyl-
oid models of AD examined have increased TREM2
RNA and protein levels [162, 200, 210–214]. This upreg-
ulation of TREM2 expression occurs shortly after the
onset of pathology and largely seems to correlate with
amyloid burden [85, 157, 215] and the association of
myeloid cells with amyloid plaques [207, 208]. Tau models
of AD also show increased TREM2 levels [211, 216], how-
ever, TREM2 is only increased long after neurofibrillary
tangle development in these models [211], consistent with
TREM2 upregulation at late stages of disease progression
in postmortem AD brain tissue [207]. Several studies have
sought to determine what aspect of AD pathology drives
TREM2 expression. TREM2 is upregulated in myeloid
cells associated with plaques [158, 162, 212, 213, 217, 218],
and specifically, TREM2 is highly expressed on myeloid
cell processes in contact with plaques [219]. In support of
a plaque-driven upregulation in TREM2 expression, Varvel
and colleagues [217] depleted microglia from the brains of
an AD mouse model and allowed the brain to repopulate
with new myeloid cells. These new cells that repopulated
the brain initially failed to associate with plaques, but
eventually became plaque-associated, and coordinately
upregulated TREM2 expression. Furthermore, stereotactic
injection of beta-amyloid 42 (Aβ42) into the cortex and
hippocampus of wild-type mice was sufficient to induce an
upregulation in TREM2 transcripts within 24 h [214].
Together, these findings suggest that amyloid can increase
TREM2 expression in myeloid cells. To determine
whether this effect was cell-autonomous, cultured micro-
glia were treated with Aβ, though these studies have so far
produced inconsistent results with respect to TREM2
expression [106, 214]. Significantly, Melchior and col-
leagues [158] found that there was no effect on cultured
microglia treated with beta-amyloid 40 (Aβ40) on TREM2
levels, but if they added Aβ40 to mixed glial cultures, this
did result in upregulation of TREM2 on microglia by flow
cytometry. This suggests that, at least this Aβ species may
drive TREM2 expression through feedback from other cell
types, though the signals that mediate Aβ-induced upregu-
lation of TREM2 on myeloid cells are not yet known.
TREM2 expression by peripherally derived macrophages in
the AD brain
Not all myeloid cells associated with plaques express
TREM2 [158, 162]. Investigation of which subset of mye-
loid cells upregulated TREM2 in the AD brain has yielded
conflicting results. Some findings suggest TREM2+ cells
may be peripherally derived macrophages rather than
brain resident microglia. Jay and colleagues [162] found
that TREM2 was expressed on CD45hi myeloid cells
which expressed the monocyte marker Ly6C and not the
microglial-specific marker P2RY12. Following toxoplasma
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gondii infection in 5XFAD mice, Mohle and colleagues
[220] found that TREM2 was expressed most highly by
C-C chemokine receptor type 2 (CCR2)+Ly6CloF4/80+
cells in the brain, a marker signature of peripherally
derived macrophages. TREM2 expression in other disease
models, including basal cell carcinoma [138], sciatic nerve
transection [221] and colonic mucosal injury [189], was
found to be upregulated coincident with the peak of
macrophage infiltration into the tissue. In contrast, others
have detected TREM2 expression on “dark” microglial
cells in the brain, which are 4D4+ and 4C12−, a marker
signature consistent with resident microglia [215]. Wang
and colleagues [222] also performed experiments in which
age-matched CD45.1 WT donors were parabiosed with
CD45.2 AD mouse models and were not able to detect
CD45.1 cells in the brains of the AD mice. Indeed, the
contribution of peripherally derived macrophages to NDD
pathologies has a long and controversial history. However,
if TREM2 is expressed on these cells, it suggests they may
play a key role in modulating pathology, and thus this
issue should continue to be explored.
TREM2 structure and signaling
The structure of full-length TREM2
TREM2 is a single pass transmembrane protein whose
ligand binding domain includes an extracellular Ig-like
domain [223] with N-linked glycosylation sites [133, 136,
170, 224], phosphorylation sites and disulfide bonds
which are thought to perform important structural roles.
The transmembrane domain anchors TREM2 to the
membrane and contains the intramembraneous lysine
residue necessary for association with its intracellular
membrane adaptor, DAP12. This is followed by a short
cytoplasmic tail with no established function. Disease-
associated variants of TREM2 alter many of these struc-
tural elements (Fig. 1). Many variants are found in exon
2 and may change the structure of its ligand-binding
domain, impacting the affinity of TREM2 for different
ligands. For example, the Y38C variant associated with
PLOSL and FTD is predicted to alter an important
flanking sequence of the cysteine residues which form
TREM2’s disulfide bonds [36, 223]. Likewise, glycosyla-
tion is affected in cells transfected with Y38C and
T66 M TREM2 variants [225], though not in several
other variants examined [48]. Glycosylation of the R47H
variant was also found to be reduced [225], though not
to the same extent as the other TREM2 variants in vitro.
In humans expressing the R47H variant there were no
significant differences in the level of glycosylation [132]
but there were differences in the pattern of glycosylation
[133, 224]. TREM2 variants can also affect other import-
ant structural motifs of the TREM2 protein such as those
required for DAP12 association, and overall protein fold-
ing and stability. T66M and Y38C variants [223] along
with V126G are predicted to be important for protein
packing. Consistent with impaired protein folding, T66M
and Y38C variants exhibit enhanced proteasomal degrad-
ation [129]. The R47H variant has been predicted to im-
pair protein stability [226], but transfected R47H-TREM2
constructs actually have an increased half-life relative to
WT TREM2 and are resistant to proteasomal degradation
in the endoplasmic reticulum (ER) [224]. NDD-associated
TREM2 variants located on the surface of the protein
(R62H, T96K, D87N and R47H), are not predicted to sub-
stantially alter TREM2 structure [223, 227] but instead
affect ligand binding [223]. As the structure of TREM2
and disease-associated variants continue to be resolved,
we will gain better insight into the organization of struc-
tural features essential for TREM2 function.
The structure and production of soluble TREM2
TREM2 can also be produced as a soluble protein (Fig. 3).
Soluble TREM2 (sTREM2) has been detected in the
supernatants of mouse [225] and human cells in culture
[198, 225]. It has been proposed that sTREM2 could be
produced by both alternative splicing and proteolytic
cleavage. Insertions [161] or frameshifts [228] preceding
exon 4 terminate the transmembrane domain and are pre-
dicted to yield a soluble product. In human brain tissue, at
least three TREM2 isoforms have been detected [51], with
isoform 1, encoding the full-length protein, being the most
highly expressed [122]. Meanwhile, the transcript encod-
ing a 219-residue splice isoform is expressed to a lesser
extent than isoform 1 in the hippocampus of AD patients
[132], whereas the degree of expression of the 222-residue
splice isoform has yet to be resolved. Based on RNA se-
quencing data in AD mice, 15–20% of transcripts were
predicted to be alternatively spliced [208]. Notably, these
alternative transcripts have been identified in human
monocytes [228], and in AD brain tissue [51, 132]. Evi-
dence of elevations in expression of TREM2 exons 3 and 4
in advanced AD cases by microarray-based gene expres-
sion analysis [229] is suggestive of TREM2 alternative spli-
cing in AD [51, 132, 228]. The expression of full length
and splice isoforms of TREM2 are strongly correlated in
AD tissue, suggesting all TREM2 isoforms may be coordi-
nately regulated [132]. DNA methylation within the body
of the gene has been shown to impact alternative spli-
cing [123], and as TREM2 can be methylated within
exon 2 [122], it is possible that context-dependent changes
in methylation may also result in altered splicing. However,
direct evidence that alternatively spliced mRNAs are trans-
lated is lacking.
The sequential proteolytic processing of TREM2 has de-
finitively been shown to generate sTREM2 [132, 225, 230].
In vitro inhibitor studies revealed full-length TREM2 is
proteolytically cleaved by a disintegrin and metalloprotein-
ase domain-containing protein (ADAM10) resulting in
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shedding of the ectodomain [136, 225, 230]. Detection of
TREM2 C-terminal fragments (CTFs) within cell lines
[133, 225, 230] and human brain extracts [231] is suggest-
ive of a two-step proteolytic cleavage event of TREM2.
Following ectodomain shedding by ADAM10, the
remaining membrane-associated TREM2 C-terminus
undergoes intramembrane proteolysis by γ-secretase to
release its intracellular domain [230]. γ-secretase cleavage
of TREM2 results in accumulation of TREM2 CTFs, with-
out a corresponding increase in full-length TREM2 at
the plasma membrane upon γ-secretase inhibition
[133, 230, 232]. It is not known how this process is
regulated, but it is known that TREM2’s adaptor protein
DAP12 is required for sTREM2 production, at least in
some contexts [149].
Whether the production of sTREM2 in AD occurs by
alternative splicing or ectodomain shedding is unclear. It
may be cell-type and context dependent as different cell
types showed either an up- (dendritic cells) or downreg-
ulation (microglia, monocytes) of the TREM2 splice
transcript levels when stimulated by LPS [161, 228].
IL13 and IL4 were also shown to enhance sTREM2 pro-
duction in bone marrow derived macrophages [149].
This is consistent with studies examining other members
of the TREM family as TREM1 [233–235] and TREM-
like transcript-1 [236] which also produce cell-specific
protein products.
TREM2 variants linked to AD and other neurodegenera-
tive diseases can alter soluble TREM2 generation. TREM2
variants can drive novel TREM2 splicing [28, 32] such as
the PLOSL-associated TREM2 variant c.482 + 2 T > C in
which conversion of a single nucleotide at a splice-donor
consensus site within intron 3 results in the deletion of
exon 3 in addition to exon 2 and/or exon 4 [18]. This is
proposed to produce soluble protein products [28] lacking
either the transmembrane (TM) domain or both the TM
and ectodomain. While most TREM2 variants are
expressed in all isoforms of TREM2, there are disease-
associated variants expressed only in the alternatively
spliced isoforms of TREM2 [15, 16, 51, 58, 83]. Several
reports have also demonstrated that TREM2 variants
T66M and Y38C yield significant changes in sTREM2
release by cultured cells [86, 225]. This was also evident in
individuals homozygous [203, 225] and heterozygous [86]
for the T66M variant, exhibiting a loss or reduction in CSF
levels of sTREM2, respectively. Other case reports showed
disease-associated TREM2 variants lowered CSF sTREM2
levels compared to a non-carrier group [86]. While some
have reported decreased levels of sTREM2 and TREM2
intracellular domain (ICD) production in vitro with the
R47H variant [224], the TREM2 R47H variant acted simi-
larly to wild-type in sTREM2 production in other in vitro
assays [225] and AD patients carrying the R47H variant
had elevated levels of CSF sTREM2 [86]. There was a
trend for higher transcript levels of a 219-residue TREM2
splice variant in cortices of late-stage AD cases with the
R47H risk allele compared to significant elevation in this
splice isoform in non-carrier AD cases [132]. These data
altogether suggest that different TREM2 variants have dis-
tinct effects on sTREM2 levels.
Subcellular localization of TREM2
In addition to altering proteolytic cleavage, the localization
of TREM2 within the cell can greatly impact TREM2
signaling, and its trafficking appears to be a highly
dynamic process. In homeostatic conditions, TREM2
seems to be primarily found intracellularly [237], associat-
ing with the trans-Golgi network [156, 200, 238] and in a
population of exocytic vesicles [238]. These vesicles
appear to be continuously shuttled to the membrane, a
process which can be rapidly induced by increases in Ca2
+ in response to ionomycin [238]. It is not clear what
other specific stimuli or disease contexts result in changes
in TREM2 localization within the cell, but this will be
critical to understand TREM2’s functional role in these
contexts. TREM2 is recycled from the membrane in
clatherin-coated vesicles in a beclin-1 [239] and Vps35-
dependent manner [239, 240]. Vps35 mediates recycling
of TREM2 from the membrane via retromer complexes
[240]. When this process is blocked, TREM2 increases its
association with the lysosome and is degraded [240].
TREM2 variants can impact TREM2 localization within
the cell. In cells in which TREM2 variants were trans-
fected, T66M and Y38C [48, 133, 223, 225, 237] as well as
other variants [48] significantly reduced TREM2 surface
expression. These variants increased the localization of
TREM2 with the ER [133, 225], which may indicate
impaired protein folding. The R47H variant was found to
either not alter surface expression [48, 133] or reduce sur-
face expression of TREM2 to a lesser extent [225]. Unlike
the other variants, R47H TREM2 was mostly localized to
the trans-Golgi network rather than the ER, comparable
to the WT receptor [133, 225]. However, Yin and col-
leagues [240] did find that the R47H variant had reduced
association with Vps35, resulting in increased lysosomal
degradation following recycling of the receptor from the
surface. Overall, this suggests that variants may, in part,
impact TREM2 function by altering the localization of
TREM2 within the cell. While TREM2 has been proposed
to play a functional signaling role exclusively on the cell
surface, this could also impact possible functional roles of
TREM2 in other cellular compartments.
TREM2 ligands
Despite substantial efforts, the identity of the biological
ligands of TREM2 remains controversial (Fig. 4).
TREM2 is known to modulate myeloid cell activity in
response to microbial products [241], which led several
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groups to test bacteria as a possible source of TREM2
ligands. Using a TREM2-Fc fusion protein that consists
of the extracellular ectodomain of TREM2 attached to
the Fc-portion of human IgG, TREM2 was found to bind
to some bacteria [242, 243], including Gram-positive (S.
aureus) and Gram-negative species (E. coli, F. tularensis),
but not S. cerevisiae [244, 245], Salmonella or Typin-
murin [246]. TREM2 was specifically found to bind highly
anionic bacterial products [244] and pertussis [247] and
cholera [248] toxins. In addition to microbial products,
TREM2 was also reported to bind to high molecular-
weight nucleic acids [160] and heat-shock protein 60
[249], that were further shown to initiate TREM2 signaling
in reporter cell lines. While some of these interactions
were found to be of relatively low affinity [249], recogni-
tion of many molecules like carbohydrates and glycans
induce only minimal biological signaling at low densities,
but at high densities when receptors are forced into closer
contact, can create strong biological effects [250]. Indeed,
glycosaminoglycans and specifically heparin sulfate were
found to modulate TREM2 binding [223] and it has been
suggested that this may result in clustering of TREM2 on
the membrane, thus potentially modulating TREM2
binding to other ligands [251].
Fig. 4 TREM2 signaling and function. TREM2 has been proposed to bind to a variety of different ligands, categorized here by lipids, lipoproteins
and ligands associated with damage- or pathogen-related molecular patterns. These ligands bind to the TREM2 receptor. Following ligand binding,
TREM2 can associate with DAP12 homodimers or DAP12/DAP10 heterodimers to mediate downstream signaling. This signaling requires
phosphorylation of the adaptor, following which activating (shown on left in green) or inhibitory (shown on right in red) signaling components
can bind. These activating components have been shown to initiate different downstream pathways that lead to cell proliferation and differentiation,
survival, phagocytosis, chemotaxis and inflammation. While many other signaling components are thought to play a role downstream of TREM2
activation, only those validated as part of the signaling pathway responsible for the listed functions have been included here. Association with
inhibitory components is thought to prevent activation of these downstream pathways. Lipids: PE [254, 96], PS [96, 144, 196, 222, 254], PA [96, 222,
254], PG [254, 222, 96], PC [144, 196, 222, 96, 254], PI [196, 222, 96], CL [96, 254, 222], SM [196, 222, 96, 254], LA [254, 222], SA [144, 196, 222, 96], Apo-/li-
poproteins: ApoE [95, 96, 94], ApoJ [94], ApoA-1 [94, 96], ApoA-II [94, 96], LDL, HDL [94, 144, 93], PAMP/DAMPs: [244, 245], (−) bacterial products (LPS,
LTA) [244], Nucleic Acids [160], Heat Shock protien 60 [249], Apoptotic cells [95, 153, 160, 96, 222], Macropahages [252], Astrocytoma cells [244]
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Unidentified TREM2 ligands were also detected by
TREM2-Fc binding to the cell surface of macrophages
[252], human astrocytoma cells [244], dendritic cells
[253], N2A cells [153, 223], THP-1 cells [223] and apop-
totic cells [160]. In support of these findings, TREM2
deficiency partially impairs microglial recognition of
apoptotic cells [94, 153, 160]. Recent studies have dem-
onstrated that TREM2 binding to these cells is sensitive
to proteinase K, suggesting the receptor binds to protein
[223], perhaps complexed with proteoglycans.
It had previously been shown that members of the
TREM family recognized lipid ligands [254], and lipids
may also help mediate the interaction of TREM2 with
ligands on the cell surface. Polar lipids found on the
cell surface were assessed as possible TREM2 ligands
[223, 242, 254], using lipid arrays [96] and reporter
assays [196, 222]. While anionic lipids seemed to produce
among the highest levels of response, additional factors
that influence the particular lipids that TREM2 recognizes
requires further study. This lipid binding may allow
TREM2 to sense changes in the local environment as
exemplified by TREM2-positive cells binding to external-
ized phosphatidylserine on apoptotic cells [153] and myelin
debris [196].
Some studies suggest that TREM2 may bind lipids in
cis with other protein-based interactions [223]. TREM2
has also been reported to bind to lipoproteins, including
Apolipoprotein A1 (ApoA-I), clusterin (CLU), and low
density lipoprotein (LDL), though ApoE has been most
widely demonstrated to bind to soluble TREM2-Fc. This
binding seems to occur independent of ApoE isoform
[94–96, 255] and be dependent on residues 130–149
[255]. Because TREM2 binds to lipids, the lipidation sta-
tus of ApoE and other apolipoproteins could dictate their
binding affinity to TREM2. Several studies [95, 96, 255]
demonstrate that TREM2-ApoE binding is not dependent
on lipid loading. However, others have found that lipida-
tion was necessary to drive TREM2 binding [94]. Lipid
association is reported to be necessary for TREM2 binding
to ApoE, ApoA-I and ApoA-II from cynomolgus macaque
CSF and serum [96]. ApoE binding to TREM2 was found
to induce TREM2 signaling in NFAT reporter cell lines
[255], though how its binding to TREM2 would alter
signaling in vivo remains to be determined. Because ApoE
can bind to apoptotic cells [95] and amyloid plaques
[95, 96], it has been proposed that an interaction
between TREM2 and ApoE may indirectly allow it to
mediate recognition and phagocytosis of these sub-
strates. This may be important in the recognition of
AD-related stimuli by TREM2, because TREM2 was
found not to bind to plate-bound Aβ [222], but did bind
to areas around amyloid plaques in an AD mouse model
[158]. However, the possibility of TREM2 binding directly
to Aβ, in addition to these indirect interactions, has not
been fully excluded. Together, these data indicate that, in
addition to protein – proteoglycan complexes, TREM2
may also bind to lipids and protein-lipid complexes.
AD-associated TREM2 variants including R47H,
R62H, D87N and T96K, are found on the surface of the
protein, and impact ligand binding [223]. Studies
employing a TREM2 R47H-Fc chimeric protein revealed
the R47H mutation significantly reduces TREM2 binding
to cells [223], ApoE [96] including all three isoforms
[95] and its lipidated form [94], other lipids [144, 222],
apolipoproteins [94, 96] and lipoproteins [144]. TREM2
variants at either the same residue (R47A, R47E and
R46A) [96] or with a similar R-to-H substitution (R62H)
[94, 144] as R47H similarly disrupted TREM2 recognition
of apolipoproteins [94] or cells [223]. However, R62H and
R52H variants demonstrated relatively comparable lipid
detection to WT TREM2 [144]. Other variants residing
within the TREM2 ectodomain (Y38C, T66M, K48M)
effectively abolished TREM2 binding to proposed ligands
[94], while those located on the ectodomain proximal to
the stalk region of TREM2 (D87N, T96K) exhibited
enhanced interactions with some ligands [144, 223], while
decreasing association with others [94]. TREM2 variants
within the stalk region (H157Y, E151K, R136W) or intra-
cellular domain (L211P) had no significant impact on
ligand binding. The differences among these disease-
conferring TREM2 variants’ recognition of cells, lipids,
lipoproteins and apolipoproteins may alter how they
impact downstream signaling. However, it remains unclear
whether the ligands identified thus far are the relevant
binding partners of TREM2 in vivo and mediate the
receptor’s ability to respond to damage or infection in
the CNS. Future work establishing the full array of
physiological TREM2 ligands, and how variants impact
these interactions will be instrumental in elucidating
the role of TREM2 on myeloid cells in response to
different pathologic stimuli.
TREM2 associates with the intracellular adaptor DAP12
Because the major isoform of TREM2 has only a short
cytoplasmic tail, it requires the intracellular adaptor
DAP12 [136, 256] to mediate several of its signaling
functions [139, 143]. Along with TREM2, DAP12 is
required for signaling of other TREM family members
[242], MDL-1, and Siglecs and can be used as an adaptor
for other receptors critical for regulating myeloid cell
function including CSF1R and toll like receptors [257].
In some contexts, cross-talk among these receptors has
been shown to occur at the level of DAP12 availability.
In order to associate with the membrane, DAP12
requires the presence of its receptors [256]. Indeed, DAP12
is clustered at the same area of the membrane where
TREM2 is highly upregulated on myeloid cell processes in
contact with plaques in an AD mouse model [258]. At the
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membrane, DAP12 can associate with other DAP12
molecules to form homodimers through cysteine resi-
dues in its short extracellular domain [259]. In some
contexts, DAP12 can also heterodimerize with DNAX
activation protein of 10 kDa (DAP10) [260] which can
modify downstream signaling cascades. It is not known
whether DAP12 complexes constitutively associate with
TREM2 or whether this is induced upon ligand binding
in vivo but recent data using a split luciferase assay
found that TREM2-DAP12 association in transfected
HEK cells was primarily driven upon TREM2 stimula-
tion [237]. Interestingly, the T66M TREM2 variant but
not R47H or S116C variants enhanced the constitutive
association with DAP12 in this system [237]. Regard-
less, activation of TREM2 and other DAP12-associated
receptors results in tyrosine phosphorylation of DAP12
within its immunoreceptor tyrosine-based activation
motifs (ITAM) by src family kinases casein kinase II at
residues 85–88 and at residues 79–81 by PKC [259]. This
phosphorylation occurs only when DAP12 is receptor-
associated [139] and serine / threonine phosphorylation of
the ITAM motifs are required for signaling [139].
TREM2 signaling downstream of DAP12
These phosphotyrosine residues on the DAP12 ITAM
serve as docking sites for a number of molecules that
initiate signaling cascades that activate an immune
response. There are several immune stimulating mole-
cules that associate with DAP12 in response to TREM2
activation (Fig. 4). Crosslinking TREM2, commonly used
to mimic TREM2 activation, can result in recruitment of
DAP10, PI3K or LAB to the TREM2-DAP12 complex.
In turn, these molecules are activated through tyrosine
phosphorylation, principally by ITAM-associated Syk
and go on to activate downstream signaling components,
including Akt, Rac, Vav and MAPKs, including ERK
[129, 136, 139, 159, 182, 260–263]. These initiate
changes in gene expression and cytoskeletal rearrange-
ment which mediate many downstream cellular func-
tions associated with immune cell activation [264].
While ITAM domains are typically activating, they can
be inhibitory in certain contexts [265, 266]. When the
ITAM motifs of DAP12 are partially phosphorylated
[267], inhibitory phosphatases SHIP, SHP and the
adaptor downstream of kinase 3 (DOK3) are recruited to
the TREM2-DAP12 signaling complex. These molecules
inhibit immune activation [265, 268–270], possibly
through blocking DAP10, PI3K, and Syk association with
the TREM2-DAP12 complex and preventing activation
of ERK, Vav3 and calcium mobilization [260].
Whether signaling through DAP12 results in activation
or inhibition of the immune response seems to be receptor-
and stimulus-dependent. Activation of TREM2 and mye-
loid DAP12-associating lectin 1 (MDL1) but not SIRPβ
enhanced association of the inhibitory SHIP1 with DAP12
[260]. Similarly, macrophage colony stimulating factor
(MCSF) alone but not MCSF and RANKL induced
localization of SHIP1 to DAP12 [260]. Even different levels
of the same stimulus can induce association of TREM2-
DAP12 with different downstream signaling components.
For example, Peng and colleagues [270] found that a low
dose, but not a high dose of LPS resulted in association of
DAP12 with DOK3. This served to dampen the cellular
response to LPS, as DOK3 deficiency increased down-
stream signaling components, cytokine production and
death of mice administered an otherwise sub-lethal dose of
LPS. However, at high doses of LPS treatment, DOK3 did
not associate with DAP12. SHIP1 was also shown to
moderate the response of TREM2-induced proliferation.
When SHIP1 deficient preosteoclasts were exposed to an
activating TREM2 antibody, osteoclast formation was
upregulated an additional 4-fold [260].
Whether DAP12 serves to activate or inhibit the
immune response depends on the receptor it is associ-
ated with, the stimulus used to activate that receptor
and the strength of that stimulus. It may also depend on
availability of different downstream signaling compo-
nents locally at the membrane, their relative expression
in the cell [262] or other environmental factors [271].
Much of the signaling data thus far was performed in
cultured osteoclasts, and future studies may find that
other cell types use distinct signaling mechanisms.
Whether TREM2 signaling is activating or inhibitory in
the context of disease is also not known, and a greater
understanding of the different TREM2 pathways that are
relevant in disease will be instructive. Interestingly,
SHIP1 variants also confer risk for AD, and it is thought
that these variants result in a change in the transcrip-
tional start site of SHIP1 resulting in a protein that lacks
its SH2 domain which is necessary for association with
ITAMs and immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) [272]. This suggests that these inhibitory
components that associate with TREM2 deserve atten-
tion moving forward in understanding immune-related
pathways that are important in AD.
Other TREM2 signaling complexes
There is a general consensus that TREM2 likely acts as a
homodimer or homomultimer to induce downstream
signaling. This is a common mechanism of activation of
other receptors with similar structures to TREM2 in
which ligand binding induces complex formation and
initiates downstream signaling cascades. Almost all stud-
ies examining TREM2 signaling have provoked TREM2
dimerization using antibody-mediated crosslinking to
induce signaling [136]. However, there is also evidence
that TREM2 can associate with other receptors, includ-
ing PlexinA1 [273, 274]. Other studies are suggestive
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that TREM2 could also bind to TREML1 [236] through
co-IP experiments or CSF1R due to their close linkage
in network analyses [101] and the strong commonalities
in their downstream pathways [222, 275]. While these
last two interactions remain to be validated, it is
certainly possible that TREM2 also acts through these
alternative heteromeric complexes. Whether this is regu-
lated by the cell type or context, and whether this is an
important role of TREM2 endogenously in the context
of NDDs, remain to be determined.
Biological actions of sTREM2
The biological roles of sTREM2 have been controversial.
Initially sTREM2 was postulated to act as a decoy recep-
tor opposing full-length TREM2 function. A soluble ver-
sion of a closely related TREM family member, sTREM1,
modeled by a TREM1-Fc fusion protein, competes with
its membrane-bound form to block TREM1 signaling
[276] and produces opposing effects on inflammation
and survival following LPS injection in mice [277]. Soluble
TREM2 may similarly act as a decoy receptor to negatively
modulate TREM2 signaling [198, 225]. In support of this,
in vitro a chimeric TREM2-Fc protein used to model
soluble TREM2 inhibited osteoclastogenesis, a process
that requires TREM2-DAP12 signaling [278].
Recent studies suggest that sTREM2 may have its own
biological function. Exogenously applied sTREM2 was
internalized by cultured bone marrow derived macro-
phages, and promoted survival in cells lacking TREM2
expression [149]. However, sTREM2 failed to rescue
phagocytosis in TREM2 deficient bone marrow macro-
phages in culture [279]. Recent data also demonstrate
that treatment of microglial cell lines with TREM2-Fc or
a HEK-cell produced sTREM2 peptide increases survival,
in line with full-length TREM2 function [14]. This study
also found that sTREM2 strongly induced an inflamma-
tory response in culture models of microglia. These data
suggest that there are important biological roles of
sTREM2 other than acting as a decoy for the full-length
TREM2 receptor. The mechanisms underlying sTREM2
function are not yet well understood, but interestingly,
does not require the presence of full-length TREM2 or
its intracellular adaptor DAP12 [14].
The signaling role of TREM2 CTFs is also starting to
be explored. In the absence of γ-secretase activity,
membrane-associated TREM2 CTFs have been proposed
to either promote TREM2 anti-inflammatory signaling
in response to LPS [280], or impair TREM2 signaling by
sequestering DAP12 from interacting with full-length
receptors [230], reducing DAP12 phosphorylation and
downstream PLCγ activation [230, 232] along with
TREM2-mediated phagocytosis [232]. Production or
stabilization of CTFs on the membrane may also provide
a point of cross-talk through which TREM2 could
modulate the signaling of other DAP12-associated
receptors. It is clear that further study will be necessary
to gain insight into how these soluble TREM2 products
impact signaling both of TREM2 and other pathways
critical to innate immunity.
TREM2 function
TREM2 regulates myeloid cell number
While TREM2 expression and signaling are context-
dependent, there are some commonalities in TREM2
function that have been found across the diverse cell
types and environments in which it has been studied
(Fig. 4), one of which is regulating myeloid cell number.
The impact of TREM2 on myeloid cell number outside
of the context of disease or stimulus is not completely
clear. While knocking down TREM2 in primary micro-
glia lead to reduced cell number [106], it had no effect
on osteoclasts derived from peripheral blood mono-
nuclear cells (PBMC’s) from PLOSL TREM2 E14X
carriers lacking TREM2 expression [19] and microglial
numbers were the same up to 1 year of age in mouse
models lacking TREM2 expression. However, crosslink-
ing TREM2 did promote an increase in osteoclast num-
ber in culture [143]. What is clear is that TREM2 has an
effect on increasing myeloid cell number in response to
inflammation or disease. TREM2 deficiency was shown
to prevent increases in the brain myeloid cell popula-
tions in response to traumatic brain injury [98], ischemia
[160, 193], aging [196], and in the initial response to
demyelination [196], though it did increase the number
of cells in a model of sepsis [170].
TREM2 deficiency also prevented local increases in
myeloid cells around plaques in AD. Amyloid plaques
are typically surrounded by a rapidly recruited [281, 282]
cluster of activated myeloid cells in AD human brain
tissue [283, 284] and in AD mouse models [285]. Recent
evidence demonstrates reduced myeloid cell accumula-
tion around amyloid plaques in TREM2 hemizygous
[222, 258, 286], and TREM2- [145, 162, 222, 258, 287]
and DAP12-deficient [258] AD mouse models, as well as
in postmortem AD human brain tissue from individuals
harboring the TREM2 R47H variant [60]. These data
illustrate that TREM2, and its adaptor protein, DAP12,
are required for myeloid cell accumulation around amyl-
oid plaques. While Wang and colleagues [145, 222]
found that TREM2 deficient AD mice had a decrease in
total brain myeloid cells, others found that this was
primarily driven by the specific loss of plaque-associated
myeloid cells [258, 287]. Together, this suggests that
TREM2 is important for myeloid cell expansion in
response to disease. Evidence suggests that in various
contexts, TREM2 is important for myeloid cell survival,
proliferation and chemotaxis, all of which could lead to
disease-associated increases in myeloid cell number.
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TREM2 enhances myeloid cell survival
TREM2 has been shown in multiple contexts to be
important for cell survival. Osteoclasts [261] and bone
marrow derived macrophages [149] from TREM2 defi-
cient mice, and liver cancer [186] and glioma cell lines
[183] in which TREM2 was knocked down had increased
levels of caspase 3, Bcl-2-associated X protein (bax),
Annexin V and TUNEL positivity, all suggesting that
TREM2 deficiency enhanced apoptosis. Similarly,
primary microglia and the BV2 microglial cell line with
reduced TREM2 expression had decreased survival,
along with decreased levels of elements of the survival-
related Wnt/β-catenin pathway [13]. Conversely, TREM2
activation through receptor crosslinking increased
survival of monocyte-derived dendritic cells [136] and
osteoclasts [260]. In culture, microglia derived from
TREM2 deficient mice did not show more cell death at
baseline, but when levels of CSF1, an important factor
for the maintenance of microglial survival, were reduced,
TREM2 deficient microglia were more likely to undergo
apoptosis [222]. This was also found to be the case in
bone marrow derived macrophages [149]. In an AD
mouse model, TREM2 deficiency also increased the
number of plaque-associated myeloid cells which were
TUNEL+ [222]. Taken together, these studies suggest
that TREM2 is protective against apoptosis, especially
under stressful cellular conditions.
TREM2 enhances myeloid cell proliferation and
differentiation
TREM2 may also increase cell number through promoting
myeloid cell proliferation. In glioma cell lines [183], liver
cancer cell lines [186], and primary microglia [13],
reduced levels of TREM2 led to cell cycle arrest. The
number of proliferating myeloid cells were also decreased
in vivo in response to demyelination [288], colonic muco-
sal injury [189] and in AD mouse models [145, 287]
lacking TREM2 expression. While the mechanisms of
this regulation of proliferation are not clear, TREM2
deficiency in cultured osteoclast precursors prevented
CSF1-mediated proliferation [261], a process also crit-
ical for proliferation of many macrophage populations,
including brain myeloid cells. It has been suggested that
TREM2 may interact with the CSF-1 receptor to medi-
ate these effects. In dendritic cells derived from PLOSL
patient PBMCs expressing Q33X and V126G TREM2
variants, gene expression profiling identified “negative
regulation of proliferation” as a genetic pathway which
was significantly increased in variant carriers compared
to controls [135]. In addition to being important for
directing proliferation of the cells in which it’s expressed,
TREM2 might also promote a myeloid cell phenotype that
directs proliferation of other cells in the surrounding
microenvironment. TREM2 is highly upregulated during
organogenesis when macrophages release factors to pro-
mote proliferation of surrounding cells [137], in tumor
associated macrophages where analogous macrophage-
driven trophic support occurs [183], and following CNS
trauma where myeloid cells serve as an important source
of neurotrophic support during tissue repair [289]. Inter-
estingly, TREM2 is strongly upregulated by neural stem
cells [290] and ESC-derived oligodendroglial precursors
[291]. A relationship between TREM2 expression and
neurogenesis has not yet been explored, but given the
influence of TREM2 of proliferation on other cell types,
this may warrant further examination.
TREM2 may also influence cell differentiation. Differen-
tiation was impaired in osteoclasts derived from PLOSL
patients expressing TREM2 variants [19] and in RAW
macrophages deficient for TREM2 through a PlexinA1-
dependent pathway [274]. However, Otero and col-
leagues [261] demonstrated that mouse-derived TREM2
deficient preosteoclasts differentiated into osteoclasts
faster. Though the role of TREM2 in cell differentiation
is not completely clear, this step in cell phenotype
determination may also contribute to the changes in
cell numbers and population observed in the context of
TREM2 deficiency.
TREM2 regulates myeloid cell chemotaxis
Another potential contributor to TREM2’s role in
expanding the myeloid cell population in the context of
disease or inflammation is by modulating chemotaxis or
migration of these cells. In culture, knocking down
TREM2 reduced chemotaxis of glioma cells in a Boydon
chamber assay in response to serum [183], and in the
BV2 microglial cell line in a scratch assay [158]. Microglia
from TREM2 deficient brain slices exhibited reduced
chemotaxis into co-cultured brain tissue from old or AD
mouse models [292]. In addition, TREM2 deficient mice
had fewer microglia migrate to the site of apoptotic
neuron injection in the brain and had slower process
extension toward a brain laser lesion as measured using
two photon microscopy [292]. Conversely, TREM2
crosslinking increased CCR7-dependent chemotaxis
[136, 139, 143]. TREM2 was also found to be co-enriched
with genes involved in purinergic signaling, a key pathway
directing microglial chemotaxis in network analyses [101],
though whether TREM2 regulates P2R-receptor mediated
chemotaxis has not been examined experimentally. How-
ever, others did not see a deficit in chemotaxis in PLOSL
patient-derived osteoclasts [19]. Kiialainen and colleagues
[135] found that PBMC’s cultured from patients with
PLOSL-associated TREM2 variants had both up- and
down-regulated components of the chemotactic response.
It may be that different components of the chemotactic
pathway and therefore different types of chemotaxis are
differentially regulated by TREM2.
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Studies have examined the effect of TREM2 on spe-
cific chemotactic pathways that are involved in tissue
infiltration by myeloid cells. Wang and colleagues [183]
found that TREM2 deficient glioma cell lines downregu-
lated CXCL10, CXCR3, MMP2 and MMP9 which are all
important in tissue invasion. In network analyses,
TREM2 was significantly co-enriched with DOCK2 and
DOCK8 which are involved in tissue transmigration
[101] and mice deficient for TREM2 had reduced
leukocyte infiltration following experimental induction
of colitis [190]. There was also decreased neutrophil
recruitment to mouse lungs in response to bacterial
infection in TREM2 deficient mice [173]. In vitro, cells
lacking TREM2 expression had reduced chemotaxis
toward CCL2 [292]. Mice lacking DAP12 were found to
have significantly reduced recruitment of peripheral
macrophages in vivo in response to cigarette smoke or
intranasal C-C motif chemokine ligand 2 (CCL2) admin-
istration, and these DAP12-chemotactic deficits were
found to be rescued by reintroducing a TREM2-DAP12
fusion construct [141]. TREM2 deficient mice also had
reduced levels of CCL2 [292] and fewer peripheral
immune cells in their brain following middle cerebral
artery occlusion (MCAO) [193]. There was a trend
toward a correlation between CCL2 and sTREM2 levels
in the CSF of human AD patients, which may suggest
that TREM2 plays a role in mediating CCL2-mediated
chemotaxis of cells in the context of AD as well. How-
ever, other studies have found no link between TREM2
and monocyte trafficking into inflammatory tissues
[149]. Future studies will be necessary to assess which
chemotactic pathways are influenced by TREM2 and
whether that includes pathways related to peripheral
immune cell infiltration into the CNS in NDDs.
TREM2 regulates phagocytic function
A well-characterized function of TREM2 is to enhance
phagocytosis. TREM2 is expressed in a subset of myeloid
cells within the CNS that have high phagocytic capacity
[215]. Across numerous in vitro studies, loss of TREM2
results in reduced phagocytosis of a variety of substrates,
including apoptotic neurons or neuronal cell lines
[95, 139, 153, 160], bone [19, 293], bacteria and bacterial
products [170, 225, 237, 249] and lipids [94, 129]. Con-
versely, TREM2 activation or overexpression enhanced
uptake of these substrates [139, 159, 214]. TREM2 expres-
sion correlated with Aβ40 uptake in BV2 cells in which
TREM2 was knocked down or overexpressed [158]. Aβ42
uptake was also reduced in TREM2 deficient primary
microglia [214, 225] and in the N9 microglial cell line
expressing a non-functional TREM2 when plated onto
brain slices from AD mouse models [279]. In agreement
with these findings, in vivo, TREM2 deficient mice have
reduced localization of Aβ within CD68+ phagosomes in
AD mouse models [258] and reduced uptake of deposited
Aβ three hours after injection into the brain [145]. To-
gether, these findings suggest that TREM2 is important
for Aβ uptake by brain myeloid cells. However, in culture,
TREM2 expression was no longer found to correlate with
Aβ uptake after pretreatment of cells with LPS [158]. A
similar effect was observed in a mouse model of sepsis
where injection of myeloid cells overexpressing TREM2
enhanced bacterial phagocytosis and survival, but not if
the mice were pretreated with LPS [180]. These findings
suggest that the mechanisms of TREM2-dependent
phagocytosis can be modified by other signals in the
microenvironment. Interestingly, the other modulatory
components present in the brain microenvironment
change throughout the course of NDDs, which could
explain some of the differences in TREM2 function at
different stages of disease progression. Outside of AD,
TREM2 is important for clearance of myelin in experi-
mental autoimmune encephalomyelitis (EAE) [159] and
peri-infarct tissue in mice following MCAO [160]. How-
ever, it does appear that the effect of TREM2 on phagocyt-
osis can be cell type specific. Sharif and colleagues [173]
found that bone marrow macrophages derived from
TREM2 deficient mice had reduced phagocytosis, but
TREM2 deficient alveolar macrophages had increased
uptake of bacteria in vitro and in vivo. R62H [94] and
R47H TREM2 variants had impaired phagocytosis [240].
This was also true in HEK cells transfected with TREM2-
DAP12 fusion constructs expressing R47H, T66M and
Y38C variants [225]. Interestingly, while all of these vari-
ants impaired uptake of polystyrene beads, T66M and
Y38C but not R47H impaired uptake of E. coli particles
[225], suggesting that different TREM2 variants could
affect recognition of specific phagocytic substrates as well
as induce changes in basal phagocytic activity reflected in
the fluid phase uptake of beads. More studies will be
required to parse out the role of TREM2 in basal phagocyt-
osis and cargo-driven phagocytosis of specific substrates.
The mechanism underlying TREM2-dependent uptake
of various substrates is not clear. While transfection of a
TREM2-DAP12 construct into CHO cells was shown to
be sufficient for uptake of Neuro2A cells [153], it may
be that TREM2 does not have to directly bind to its
phagocytic substrates, as TREM2 binding to Hsp60 was
sufficient to increase phagocytosis of bacteria [249]. If
TREM2 does not directly bind to these substrates, then
it must interact with other phagocytic pathways. It is
possible that TREM2 impacts fluid-phase phagocytosis
rather than cargo driven phagocytosis. TREM2 may also
interact with other phagocytic receptors. For example,
MerTK is essential for the phagocytosis of apoptotic
cells [294] and is upregulated on the same cell popula-
tion as TREM2 in AD [213]. Network analyses have also
shown that TREM2 is co-enriched with genes involved
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in FCγR and complement-mediated phagocytosis [101].
In support of an association between TREM2 and Fc-de-
pendent phagocytic pathways, stimulating cells lacking
TREM2 function with an antibody against the desired
phagocytic substrate did increase internalization of the
substrate, but did not rescue it back to WT levels [279].
TREM2 deficient alveolar macrophages were found to
increase phagocytosis and this was found to be
dependent on the upregulation of first component of
complement q (C1q) in these cells [173], which acts to
opsonize phagocytic substrates. It may also be that
sTREM2 plays a role in binding and directing phagocyt-
osis of substrates by these other pathways, as ADAM
inhibitors reduced sTREM2 production and decreased
phagocytosis of E. coli [225].
Some have also suggested that these findings may
reflect changes in degradation of phagocytic substrates
rather than their uptake. Forabosco and colleagues [101]
found that genes associated with lysosome activity were
co-enriched with TREM2 across the brain and in
monocyte-derived macrophages. In PLOSL patients,
there is an accumulation of large CD68+ myeloid cells,
suggesting that phagocytic uptake by these cells may be
intact [25]. In a cuprizone model of demyelination,
TREM2 deficiency was found not to impair uptake of
myelin debris, but that this debris remained in cells
longer than in controls, suggesting that degradation was
specifically impaired [288]. This was also found to be
true in TREM2 deficient macrophages which were able
to take up bacteria at comparable levels to cells expressing
WT TREM2 but were unable to kill and degrade them
[263]. However, Jiang and colleagues [214] found that in
primary microglia in which TREM2 was knocked down,
Aβ42 degradation was unaffected. Together, the exact role
of TREM2 in phagocytosis and other means of cellular
uptake and degradation of substrates from the microenvir-
onment remain unclear, though it clearly does play an
important role in these processes.
TREM2 modulates inflammatory responses
TREM2 interacts with many other inflammation-related
pathways. While TREM2 has been touted as being anti-
inflammatory, it seems that the interaction between
TREM2 and other inflammation related pathways is
actually more complex. Depending on the precise stim-
uli, the strength [260] and duration [4] over which they
are presented, the cell type and the context, TREM2 can
play different roles in the inflammatory response. In sup-
port of this, network analyses found that TREM2 was
co-enriched with both classically pro- and anti-
inflammatory gene clusters in the brain [101]. Likewise,
a microarray analysis of macrophages derived from a
PLOSL patient PBMC’s showed components of the
inflammatory response and innate immune response
were both up- and down-regulated, respectively, relative
to controls [135]. Outside of the context of injury or dis-
ease, the transcriptional profiles of TREM2 deficient
[222] or overexpressing [214] myeloid cells compared to
controls was fairly similar. It is in the context of disease
where TREM2 seems to heavily influence changes in
inflammation-related pathways.
TREM2 has been classically described as being anti-
inflammatory and several in vitro and in vivo studies are
supportive of an anti-inflammatory role for TREM2 in
certain contexts. Knocking down TREM2 in cell lines
increases levels of proinflammatory mediators such as
iNOS, TNFα, IL1β and IL6 [240] in response to apoptotic
neuronal membrane components [139], TLR ligands
[168], including LPS [159, 169, 170, 280] and Aβ42 [157].
A transient knock down of TREM2 in the P301S tau
model and in the SAMP8 model of accelerated aging also
increased inflammatory cytokine production [201, 216].
TREM2 deficiency also resulted in increased levels of
IFNγ, TNFα and iNOS [189] following colonic mucosal
injury and TREM2 knockdown or antibody-mediated
inhibition increased expression of many inflammation-
related cytokines following corneal infection [182]. More-
over, overexpressing TREM2 in cell lines, amyloid [214]
and tau models of AD [295] reduced levels of these
pro-inflammatory transcripts. Together, these studies
suggest that in some contexts, TREM2 can attenuate
inflammatory responses.
However, many other studies also support that
TREM2 can mediate or amplify inflammatory responses.
For instance, TREM2 knockdown impaired ROS produc-
tion [246, 263]. TREM2 deficient microglia are more
ramified in culture, a morphological signature of reduced
activation [160]. TREM2 deficient AD mouse models have
reduced levels of inflammation-related transcripts in both
unbiased RNA sequencing approaches [222] and in the
genes IL1β and IL6 in targeted analyses [162, 287].
Plaque-associated cells in AD mouse models deficient
[222] or haploinsufficient [286] for TREM2 also had
decreased cell soma size, surface area and increased
process length, indicative of reduced activation [222].
Recent work using single cell sequencing approaches indi-
cates that TREM2 is required specifically for a second
phase of the myeloid cell response in AD which allows
cells to fully adopt a neurodegeneration-associated pheno-
type [296]. This may be true in diverse disease contexts as
pro-inflammatory cytokine levels were also reduced in
TREM2 deficient mice following traumatic brain injury
[98], ischemia [193], lung infection [149, 173] and demye-
lination [196], where TREM2 deficient brain myeloid cells
exhibited a less activated morphology [288]. Conversely,
activation of TREM2 in a macrophage cell line increased
NO release [136], agonizing TREM2 following spinal
nerve transection increased TNFα and IL1β [194] and
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overexpression of TREM2 increased expression of IL6,
TNFα and MCP1 in mouse adipose tissue [129]. Because
these studies examined gene expression in whole tissue, it
is not clear whether these changes are due to changes in
immune cell phenotype or alteration in cell number in the
affected tissues. However, taken together, these findings
clearly indicate that TREM2 can also promote inflamma-
tory responses in certain contexts. This body of data
strongly opposes the often-cited descriptor of TREM2 as
an anti-inflammatory receptor. Future studies will be
required to delineate the molecular and environmental
determinants that govern how TREM2 contributes to the
inflammatory response in different contexts.
While the number of studies have been limited,
TREM2 variants associated with NDDs also seem to
have mixed effects on inflammatory responses. The
R47H variant impaired inflammatory responses in BV2
cells [240], yet R47H carriers with AD had increased
expression of genes related to inflammatory pathways
compared to non-carriers [57]. A variant within intron 2
of TREM2, which is prevalent in African American indi-
viduals, was found to be significantly associated with
levels of C-reactive protein (CRP), a systemic marker of
inflammation, whose expression is primarily driven by
IL6 and IL1β [110]. However, it is not clear whether this
represents a direct relationship between this TREM2
variant and systemic inflammation.
In addition to impacting the inflammatory responses
of myeloid cells, TREM2 also seems to be able to indir-
ectly feedback onto the inflammatory response in other
cells within the microenvironment, including astrocytes.
Astrocytosis, measured by glial fibrillary acid protein
(GFAP) levels, was reduced across all stages of path-
ology examined in TREM2 deficient AD mouse models
[162, 287], in areas of active demyelination [288] and
trended toward a reduction in GFAP area in mice
following ischemia [160]. However, GFAP levels were
unchanged in TREM2 deficient mice at acute and
chronic time points following traumatic brain injury
[98], suggesting that TREM2 must work in tandem with
context-dependent signals to alter astrocyte activation.
One of the characteristic features of PLOSL is astrocy-
tosis [22] and in a PLOSL patient with a TREM2 vari-
ant, GFAP levels were significantly increased in frontal
lobe tissue [28]. This suggests that TREM2 can play
multiple roles in regulating astrocyte activation depend-
ing on the precise context.
Other functions of TREM2
While regulating cell number, phagocytosis and inflam-
mation are the best studied roles for TREM2, other
studies have suggested additional roles for the receptor,
such as regulation of synaptic pruning and monitoring
of synaptic function [297]. Because of the cross-talk
between TREM2 and complement pathways and a clear
role of TREM2 and complement in phagocytosis in dis-
ease [298], it would be of interest to assess whether
TREM2 influences synaptic function by modulating syn-
aptic pruning, either normally during development or
aberrantly in the context of NDDs. Others have sug-
gested that, due to the close apposition of TREM2+ cells
to oligodendrocyte precursors during development, they
may support their function [154]. TREM2 has also been
shown to be important for angiogenesis following stroke
[160]. Because of TREM2’s proposed lipid-related ligands,
and the strong links between lipid metabolism and NDDs,
it would not be surprising if TREM2 also played roles in
this pathway. In support of this, lipid metabolism was the
most strongly altered pathway in TREM2 deficient mouse
brains following cuprizone-induced demyelination [288].
How TREM2 affects these normal functions within the
brain has not been studied, but may represent important
future areas of investigation.
Outside of the brain, studies have proposed additional
roles for the TREM2 receptor. TREM2 has been pro-
posed to play a role in adaptive immunity. Myeloid cells
expressing higher levels of TREM2 were able to increase
T cell proliferation better than those expressing lower
TREM2 levels [158]. TREM2 was also found to be co-
enriched with genes related to adaptive immunity in
gene network analyses [101]. However, others have
found that activating TREM2 through crosslinking did
not upregulate molecules involved in antigen presenta-
tion [159, 299], suggesting that TREM2-mediated stimu-
lation of adaptive immune responses may be indirect or
require additional environmental factors. TREM2 also
seems to be important for cell maturation [136] and in
particular multinucleation of osteoclasts [19, 143, 293].
It is not yet known how TREM2 might mediate these
additional functions.
TREM2 and NDD pathology
TREM2 impacts amyloid pathology in AD
The observed changes in TREM2 expression, signaling
and function with disease-associated genetic variants
ultimately translate to changes in NDD pathology. Many
studies have focused on how TREM2 and disease-
associated variants impact AD-related pathologies. Stud-
ies examining loss of TREM2 function in amyloid mouse
models initially appeared to support contradictory con-
clusions. Some groups found that TREM2 deficiency
reduced [162, 258] while others found that it increased
[222] amyloid pathology. However, recent evidence has
harmonized these results by demonstrating that TREM2
deficiency has a changing role throughout AD progres-
sion, reducing amyloid pathology early but increasing it
at later stages of disease [287]. Studies overexpressing
TREM2 in AD mouse models also found a temporal
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effect of this overexpression, which reduced pathology
early in disease progression [214] but no effect at a later
time point [300]. This is supported by Korvatska and
colleagues [60] who demonstrate accelerated disease
progression in R47H carriers compared to non-carriers
with AD. This may also explain discrepancies in human
studies of R47H carriers who found no association
between R47H carriers and non-carriers in amyloid
deposition [49] and others who found that R47H carriers
had significantly more plaques compared with non-
carriers [57]. This changing role for TREM2 throughout
progression of amyloid pathology may also reflect a
dynamic role for myeloid cells themselves. As Hickman
and El Khoury [11] posit, these brain myeloid cells may
be protective early through clearance of Aβ, but detri-
mental later in disease progression when they enhance
the inflammatory response without being effective
phagocytes. Alternatively, it could reflect how TREM2
impacts the phenotype and abundance of distinct mye-
loid cell subsets, or perhaps other microenvironmental
cues which change TREM2 downstream signaling to
favor alternative pathways. While mouse models so far
have recapitulated several aspects of TREM2 localization
and function observed in human brain tissue, it is worth
noting that there is a caveat to studying TREM2 in mouse
models of AD with PSEN mutations since γ-secretase is
also important for TREM2 CTF cleavage [232]. It is not
clear whether changes in γ-secretase activity would be
likely to greatly alter TREM2 function in vivo, but this
should be a consideration when interpreting these studies.
Interestingly, there also appears to be a difference in
the mechanism by which TREM2 affects pathology early
and late in disease progression. Early, TREM2 deficiency
decreases the number of plaques, while later in disease
progression, increase in pathology is instead driven by
increased plaque size [287]. While it’s not clear exactly
how TREM2 could modulate Aβ proteostasis early in
disease progression to impact plaque number. TREM2
was shown to impact APP processing in a genome-wide
siRNA screen [301], though since it is not neuronally
expressed, this would likely occur through indirectly
altering neuronal phenotype. Conversely, later in disease,
the association of myeloid cells with plaques has been
proposed to limit plaque growth by forming an insulated
microenvironment or barrier [258, 302]. TREM2 defi-
ciency appears to impede the formation of this barrier,
and in doing so, cause a shift from compact to diffuse
plaques [258].
TREM2 modulates neuritic dystrophy in AD
TREM2 has also been studied in AD in the context of
modifying neuritic dystrophy. Several studies have found
increased neuritic dystrophy around plaques in TREM2
deficient mice [145, 258] and in human R47H carriers
with AD [57]. TREM2 overexpression in 7-month but
not 18-month-old APP/PS1 mice had increased levels of
synaptophysin, suggesting that enhanced TREM2
expression may protect against Aβ-driven synapse loss
[157, 300]. One possible mechanism for this lies in the
larger, more diffuse plaques with high soluble Aβ affinity
[258] observed in TREM2 deficient mice late in disease
progression [287]. The relative toxicity of soluble Aβ is
well documented, including its roles in blocking long-
term potentiation [303] and inducing tau hyperpho-
sphorylation and aggregation [304, 305]. Together, these
data suggest that functional TREM2 is necessary for
microglial clustering around amyloid plaques and may
thereby form a barrier around plaques which limits
neuritic dystrophy. However, not all data support a pro-
tective role of plaque-associated myeloid cells on AD
pathology. Microglia can serve as synaptotoxic agents in
AD through complement-mediated synaptic pruning
[298]. In this way, the loss of plaque-associated myeloid
cells due to TREM2 deficiency could be beneficial.
Others suggest that it may not be that more dystrophic
neurites are formed around plaques in TREM2 deficient
mice and R47H carriers, but that TREM2 deficient mye-
loid cells are not as effective at clearing them [215].
Further evidence will be required to assess the formation
and clearance of dystrophic neurites across stages of AD
in the context of TREM2 deficiency or TREM2 variants
to assess these possible mechanisms.
TREM2 affects tau hyperphosphorylation and aggregation
in AD
The impact of TREM2 on tau pathology in AD has also
been examined. The effect of TREM2 on phosphorylated
tau (p-tau) accumulation in dystrophic neurites in AD is
not clear, with some studies showing an increase [145,
222] and others showing a decrease [162] in hyperpho-
sphorylated tau markers surrounding plaques in TREM2
deficient amyloid mouse models of AD. These different
outcomes are likely related to disease progression
dependent effects on the amyloid pathology driving this
accumulation. Less work has been done in tau models of
AD, but overexpressing TREM2 under the CD11b pro-
moter in the P301S tau model of AD resulted in reduced
hyperphosphorylated tau levels, coordinate with a
decrease in activation of two of the known tau kinases,
cyclin dependent kinase 5 (CDK5) and GSK3β [295].
Opposite effects were observed in P301S mice in which
TREM2 was knocked down [216]. In humans, TREM2
protein levels in the temporal cortex of AD patients cor-
related with tangle score and paired helical filament
(PHF) levels [164] and sTREM2 levels in CSF are corre-
lated with CSF tau levels early in clinical AD progression
[202], suggesting an important relationship between
TREM2 and tau pathology in humans. R47H patients
Jay et al. Molecular Neurodegeneration  (2017) 12:56 Page 20 of 33
had higher levels of CSF p-tau [53, 61], and a variant
located upstream of TREM2 was associated with
increased tau pathology in the brain [109]. Together,
these findings suggest that TREM2 variants may also
have an impact on tau-related pathologies in AD, though
the mechanisms governing this association are less clear.
TREM2 affects synaptic and neuronal loss in AD
Studies have also examined how TREM2 and its variants
impact neuronal and tissue loss and cognition in AD.
TREM2 protein levels in the temporal cortex of AD
patients were positively correlated with cleaved caspase
3 and negatively correlated with the presynaptic marker
SNAP25 [164], suggestive that loss of TREM2 could
impact synapse pathology. There was also a significant
reduction in neurons in layer V of the cortex in TREM2
deficient amyloid models of AD [222] and a substantial
rescue of neuronal loss when TREM2 was overexpressed
in amyloid [157] and tau [295] AD mouse models. These
changes in neuron number also correlated with a rescue
in behavioral deficits [157, 295]. Interestingly, however,
TREM2 expression levels on peripheral monocytes cor-
related with lower MMSE [128] and MoCA scores as
well as reduced gray matter volume [148]. R47H variant
carriers with AD also had reduced gray matter volume
[63] in the temporal cortex and hippocampus [61].
There was also a trend toward a reduction in hippocam-
pal volume [306] and significant decreases in other brain
regions [63] in R47H carriers even in the absence of
clinical AD. Though no changes in cognitive function
were reported in middle-aged R47H carriers [307], the
variant did correlate with cognitive deficits in older
adults with R47H variants [6]. This was also true in
healthy individuals heterozygous for NHD variants
[308]. These findings suggest that TREM2 variants may
have direct effects on neuronal loss, even in the absence
of AD pathology.
The effect of TREM2 on other NDD pathologies
Although not as extensively studied as in AD, the impact
of TREM2 on other NDD-related pathologies has also
been assessed. PLOSL patients have severe white matter
dystrophy [22] and oligodendrocytes that survive in
PLOSL patient white matter express markers of cell stress
[309] suggesting a role for TREM2 deficiency in white
matter degeneration. In cuprizone-mediated demyelination
models, TREM2 deficiency impaired recovery and in-
creased levels of axonal degeneration markers [288, 289].
In addition, injecting mice with TREM2 transduced mye-
loid cell precursors prevented EAE-induced demyelination
and ameliorated motor phenotypes [159]. In addition to af-
fecting oligodendrocyte survival and recovery following de-
myelination, TREM2 variants in PLOSL have also
elucidated other roles of TREM2 in NDDs. PLOSL patients
often experience seizures [22, 310], resulting in excito-
toxicity. One patient with a predicted loss-of-function
TREM2 PLOSL mutation had a reduction in many syn-
aptic components, including nine GABA receptor sub-
units, which could play a role in mediating this
enhanced excitability [28]. However, the mechanism
underlying this phenomenon is not well understood
and requires further study.
The effect of TREM2 on inflammation-related pathologies
TREM2 has also been shown to modify tissue loss and
behavior in several neuroinflammatory contexts. TREM2
deficiency reduced hippocampal volume loss and
improved some behavioral outcomes at chronic time
points following traumatic brain injury [98]. In contrast,
TREM2 deficient mice had increased infarct volume in
one MCAO model [160], though no change in another
study [193]. Treatment with a TREM2 agonist induced
pain behavior in mice in a DAP12-dependent manner
even in the absence of nerve injury [194]. Outside of the
brain, TREM2 deficiency results in increased body
weight and glucose and insulin intolerance in mice fed a
high fat diet [129]. TREM2 variant carriers may also
have increased risk of systemic infection [311] and
TREM2 deficiency is detrimental in the context of bac-
terial infection [149, 170, 180, 263]. Overall, in the brain
and the periphery, despite great advances in assessing
how TREM2 alters pathology, there is still no clear pic-
ture of how TREM2 mediates these diverse functional
impacts across inflammatory and disease contexts. This
will require a greater understanding of TREM2 expres-
sion, signaling and function and how these features
change in the context of pathology. While these studies
do point toward some common mechanisms by which
TREM2 might modify aspects of pathology relevant to
multiple NDDs, it is clear that the role of TREM2 in
NDDs is not simple.
The clinical relevance of TREM2
TREM2-related biomarkers
Since the identification of NDD-associated TREM2 vari-
ants, and the detection of sTREM2 in the CSF and
plasma of AD patients, there has been much excitement
about how this may translate into immune-related NDD
biomarkers and therapeutics. Elevated levels of sTREM2
were first detected in the CSF of patients with multiple
sclerosis (MS) and other inflammatory neurologic dis-
eases [312] and were found to be significantly elevated
in MS patients [313]. These findings served as an im-
petus to examine whether CSF sTREM2 might also be
changed in AD patients. Groups have reported eleva-
tions [314], reductions [225] or non-significant changes
[203] in CSF sTREM2 in AD cohorts not stratified by
disease stage (Table 1). However, as shown in Table 1,
Jay et al. Molecular Neurodegeneration  (2017) 12:56 Page 21 of 33
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
ex
pe
rim
en
ta
ld
es
ig
n
fo
r
st
ud
ie
s
th
at
ex
am
in
ed
sT
RE
M
2
in
C
SF
an
d
pl
as
m
a
St
ud
y
Sa
m
pl
e
Ty
pe
M
et
ho
d
of
sT
RE
M
2
D
et
ec
tio
n
M
ai
n
Fi
nd
in
g
(p
-v
al
ue
)
sT
RE
M
2
(p
g/
m
l),
m
ea
n
±
sd
or
m
ed
ia
n(
IQ
R)
St
ud
y
C
oh
or
t
C
on
tr
ol
s
(C
TR
)
D
ia
gn
os
tic
Pa
ra
m
et
er
s
A
ge
(y
rs
)
m
ea
n
±
sd
or
M
ed
ia
n(
ra
ng
e)
G
en
de
r
(p
er
ce
nt
fe
m
al
e)
A
po
E
ε4
+
ca
rr
ie
rs
C
rit
er
ia
C
og
ni
tiv
e
Te
st
in
g
O
th
er
G
is
pe
rt
et
al
.
(2
01
6)
[3
16
]
C
SF
EL
IS
A
↑ sT
RE
M
2
[C
TR
-M
C
I
(0
.0
1)
;
Pr
eA
D
-M
C
I
(0
.0
36
);
C
TR
-A
D
(0
.0
44
)]
Re
la
t.
to
IS
C
TR
:
40
0
±
20
0
Pr
eA
D
:
53
0
±
39
0
M
C
I:
71
0
±
42
0
A
D
:
62
0
±
40
0
Pr
eA
D
(n
=
19
),
M
C
Id
ue
to
A
D
(n
=
27
),
an
d
m
ild
A
D
(n
=
23
);
al
ln
on
-T
RE
M
2
va
ria
nt
ca
rr
ie
rs
C
og
ni
tiv
el
y
no
rm
al
su
bj
ec
ts
de
fin
ed
by
M
M
SE
sc
or
e
>
27
,
C
D
R
=
0,
an
d
ne
ga
tiv
e
A
D
C
SF
pr
of
ile
a
(n
=
45
)
N
IA
-A
A
fo
r
A
D
an
d
M
C
Id
ue
to
A
D
gr
ou
ps
M
M
SE
an
d
C
D
R;
Pr
eA
D
ha
d
M
M
SE
sc
or
e
>
27
an
d
C
D
R
=
0
M
RI
;P
os
iti
ve
A
D
C
SF
pr
of
ile
:A
β4
2
(<
50
0
pg
/m
l),
t-t
au
(>
45
0
pg
/m
l),
an
d
p-
ta
u
(>
75
pg
/m
l)
C
TR
:
60
.9
8
±
6.
83
Pr
eA
D
:
68
.5
3
±
7.
93
M
C
I:
70
.3
0
±
7.
35
A
D
:
66
.7
8
±
9.
75
C
TR
:6
3%
Pr
eA
D
:6
8%
M
C
I:
55
%
A
D
:6
9%
C
TR
:1
5%
Pr
eA
D
:4
2%
M
C
I:
52
%
A
D
:4
8%
Su
ár
ez
-C
al
ve
t
et
al
.(
20
16
)
[2
02
]
C
SF
EL
IS
A
↑
sT
RE
M
2
[C
TR
-M
C
I
(0
.0
02
);
A
D
-M
C
I
(0
.0
13
);
Pr
eA
D
-M
C
I
(0
.0
62
)]
Re
la
t.
to
IS
C
TR
:
47
0
±
20
2
Pr
eA
D
:
64
4
±
41
0
M
C
I:
80
2
±
38
0
A
D
:
72
5
±
44
0
Pr
eA
D
(n
=
63
),
M
C
Id
ue
to
A
D
(n
=
11
1)
,a
nd
A
D
(n
=
20
0)
,f
ro
m
fiv
e
ce
nt
er
s
A
sy
m
pt
om
at
ic
co
gn
iti
ve
ly
no
rm
al
su
bj
ec
ts
w
ith
a
ne
ga
tiv
e
A
D
C
SF
pr
of
ile
a ,
de
te
rm
in
ed
ac
ro
ss
fiv
e
ce
nt
er
s
(n
=
15
0)
N
IA
-A
A
fo
r
ea
ch
gr
ou
p
N
R
Po
sit
iv
e
A
D
CS
F
pr
of
ile
a
w
ith
cu
t-o
ff
va
lu
es
un
iq
ue
to
ea
ch
ce
nt
er
(re
fe
rt
o
[3
22
])
C
TR
:
62
.4
±
11
Pr
eA
D
:
70
.8
±
11
M
C
I:
74
.3
±
9
A
D
:
73
.8
±
10
C
TR
:5
9%
Pr
eA
D
:6
0%
M
C
I:
60
%
A
D
:6
2%
C
TR
:2
1%
Pr
eA
D
:5
8%
M
C
I:
52
%
A
D
:6
2%
Su
ár
ez
-C
al
ve
t
et
al
.(
20
16
)
[1
2]
C
SF
EL
IS
A
↑
sT
RE
M
2
[N
C
-M
C
(0
.0
04
)]
N
C
:
28
24
±
12
92
M
C
:
35
61
±
16
61
C
as
es
w
ith
A
D
A
D
(n
=
12
7)
fro
m
D
IA
N
co
ho
rt
N
on
ca
rr
ie
rs
(n
=
91
)
fo
r
A
D
A
D
-r
el
at
ed
m
ut
at
io
ns
fro
m
D
IA
N
co
ho
rt
Pr
es
en
ce
of
A
D
A
D
m
ut
at
io
n
(P
SE
N
1,
PS
EN
2,
or
AP
P)
as
se
ss
ed
by
D
IA
N
M
M
SE
an
d
C
D
R
A
D
C
SF
pr
of
ile
ex
am
in
ed
N
C
:
39
.5
±
11
M
C
:
40
.4
±
11
N
C
:5
4%
M
C
:5
0%
N
C
:3
4%
M
C
:2
8%
↑
sT
RE
M
2
[M
C
w
ith
C
D
R
=
0.
5
(0
.0
06
);
M
C
w
ith
C
D
R
=
1
(0
.0
44
)]
N
o.
of
Su
bj
ec
ts
pe
r
C
D
R:
C
D
R
n
0
52
0.
5
51
1
16
2
to
3
8
N
o.
of
Su
bj
ec
ts
pe
r
C
D
R:
C
D
R
n
0
88
0.
5
3
1
0
2
to
3
0
H
es
le
gr
av
e
et
al
.(
20
16
)
[3
14
]
C
SF
N
ov
el
re
ac
tio
n
m
on
ito
rin
g
as
sa
y
w
ith
U
PL
C
/T
Q
-S
M
S
↑
sT
RE
M
2
[C
TR
-A
D
(0
.0
45
7)
]
C
TR
:1
95
.6
(1
31
.0
–2
40
.7
)
A
D
:2
31
.2
(1
72
.5
–3
05
.4
)
U
K
co
ho
rt
:A
D
(n
=
37
)
C
og
ni
tiv
el
y
no
rm
al
w
ith
ne
ga
tiv
e
A
D
C
SF
pr
of
ile
a
(n
=
22
)
Re
vi
se
d
IW
G
2
fo
r
A
D
M
M
SE
Po
si
tiv
e
A
D
C
SF
pr
of
ile
a
(A
β4
2
<
55
0
pg
/m
l,
t-
ta
u
>
37
5
pg
/m
l,
p-
ta
u
>
52
pg
/m
l)
C
TR
:
69
.2
±
8.
0
A
D
:
70
.5
1
±
7.
5
C
TR
:4
5%
A
D
:5
3%
C
TR
:3
3%
A
D
:6
7%
↑
sT
RE
M
2
[C
TR
-A
D
(0
.0
31
2)
]
C
TR
:1
71
(1
53
.5
–2
41
.5
)
A
D
:2
30
(1
66
.5
–2
97
.4
)
Sw
ed
ish
co
ho
rt
:
A
D
(n
=
24
)
C
og
ni
tiv
el
y
no
rm
al
su
bj
ec
ts
(n
=
16
)
N
IA
-A
A
fo
r
A
D
or
M
C
Id
ue
to
A
D
M
M
SE
M
RI
or
C
T;
Bl
oo
d
sc
re
en
in
g
(u
ns
pe
ci
fie
d)
C
TR
:
55
.6
±
9.
7
A
D
:
64
.3
±
6.
8
C
TR
:5
6%
A
D
:5
4%
C
TR
:3
1%
A
D
:6
9%
Kl
ei
nb
er
ge
r
et
al
.(
20
14
)
[2
25
]
C
SF
EL
IS
A
↓
sT
RE
M
2
[C
TR
-A
D
(0
.0
01
)]
Re
la
t.
Va
lu
es
C
TR
:0
.3
81
(0
.2
83
–0
.5
18
)
A
D
:0
.3
09
(0
.1
78
–0
.4
36
)
A
D
(n
=
56
),
fro
m
A
D
-
co
nf
irm
ed
ca
se
s
ac
ro
ss
si
x
ce
nt
er
s
C
og
ni
tiv
el
y
no
rm
al
w
ith
ne
ga
tiv
e
A
D
C
SF
pr
of
ile
a
(C
SF
:
n
=
88
;p
la
sm
a:
n
=
86
)
N
IN
C
D
S-
A
D
RD
A
fo
r
pr
ob
ab
le
A
D
N
R
Po
si
tiv
e
A
D
C
SF
pr
of
ile
a
de
fin
ed
by
th
e
M
at
ts
so
n
et
al
.
eq
ua
tio
n:
[3
24
]
(A
β4
2/
p-
ta
u)
/
(3
.6
94
+
0.
01
05
x
t-
ta
u)
C
TR
:
60
.7
±
9.
5
A
D
:
70
.4
±
8.
9
C
TR
:6
3%
A
D
:6
8%
N
R
Pl
as
m
a
↔
sT
RE
M
2
[C
TR
-A
D
(0
.8
72
)]
Re
la
t.
Va
lu
es
C
TR
:1
.0
22
(0
.6
75
–1
.8
64
)
A
D
:0
.9
98
(0
.7
02
–1
.3
75
)
A
D
(n
=
51
),
fro
m
A
D
co
nf
irm
ed
ca
se
s
ac
ro
ss
si
x
ce
nt
er
s
C
TR
:
60
.4
±
9.
5
A
D
:
70
.7
±
9.
0
C
TR
:6
4%
A
D
:7
1%
N
R
Jay et al. Molecular Neurodegeneration  (2017) 12:56 Page 22 of 33
Ta
b
le
1
C
ha
ra
ct
er
is
tic
s
of
ex
pe
rim
en
ta
ld
es
ig
n
fo
r
st
ud
ie
s
th
at
ex
am
in
ed
sT
RE
M
2
in
C
SF
an
d
pl
as
m
a
(C
on
tin
ue
d)
H
en
ju
m
et
al
.(
20
16
)
[2
03
]
C
SF
EL
IS
A
↔
sT
RE
M
2
[C
TR
-M
C
I
(0
.4
2)
;
C
TR
-A
D
(0
.1
7)
]
C
TR
:4
40
0
(3
00
0–
57
00
)
M
C
I:
41
00
(2
40
0–
59
00
)
A
D
:4
80
0
(3
50
0–
71
00
)
N
or
w
eg
ia
n
co
ho
rt
:
A
D
(n
=
29
)
or
M
C
I
du
e
to
A
D
(n
=
21
)
C
og
ni
tiv
el
y
no
rm
al
su
bj
ec
ts
(n
=
50
)
D
SM
-II
IR
fo
r
de
m
en
tia
;
N
IN
C
D
S-
A
D
RD
A
fo
r
A
D
M
M
SE
M
RI
or
C
T
C
TR
:
66
(5
0–
86
)
M
C
I:
67
(5
5–
75
)
A
D
:
68
(5
6–
75
)
C
TR
:5
0%
M
C
I:
57
%
A
D
:4
5%
C
TR
:0
%
M
C
I:
38
%
A
D
:3
4.
5%
↔
sT
RE
M
2
[C
TR
-A
D
(0
.7
6)
]
C
TR
:3
20
0
(2
80
0–
50
00
)
A
D
:3
80
0
(2
60
0–
56
00
)
Sw
ed
ish
co
ho
rt
:
A
D
(n
=
25
)
C
og
ni
tiv
el
y
no
rm
al
w
ith
no
rm
al
A
β4
2
le
ve
ls
(>
55
0
pg
/m
l)
(n
=
25
)
N
IA
-A
A
fo
r
A
D
or
M
C
Id
ue
to
A
D
M
M
SE
M
RI
or
C
T;
Bl
oo
d
sc
re
en
in
g
(u
ns
pe
ci
fie
d)
C
TR
:
62
(4
3–
80
)
A
D
:
79
(6
1–
86
)
C
TR
:6
8%
A
D
:7
2%
C
TR
:4
%
A
D
:1
6%
Pi
cc
io
et
al
.
(2
01
6)
[8
6]
C
SF
EL
IS
A
↑
sT
RE
M
2
[C
TR
-A
D
(0
.0
15
)]
C
TR
:1
02
8
(2
44
–2
57
0)
A
D
:8
32
(1
63
–2
19
6)
Th
os
e
w
ith
m
ai
nl
y
m
ild
A
D
,n
on
-T
RE
M
2
va
ria
nt
ca
rr
ie
rs
(C
SF
:n
=
73
;
pl
as
m
a:
N
R)
,
fro
m
tw
o
ce
nt
er
s
C
og
ni
tiv
el
y
no
rm
al
su
bj
ec
ts
(C
D
R
0)
an
d
ne
ga
tiv
e
fo
r
A
D
C
SF
pr
of
ile
a
(C
SF
:n
=
10
7;
pl
as
m
a:
N
R)
N
IN
C
D
S-
A
D
RD
A
fo
r
pr
ob
ab
le
A
D
C
D
R
N
R
C
TR
:
70
.2
±
8.
5
A
D
:
76
.6
±
5.
2
C
TR
:5
3%
A
D
:4
9%
C
TR
:4
8%
A
D
:6
4%
Pl
as
m
a
↔
sT
RE
M
2
[C
TR
-A
D
(0
.7
4)
]
C
TR
:9
76
(6
5–
24
77
)
A
D
:1
01
9
(1
90
–2
54
6)
N
R
N
R
N
R
A
bb
re
vi
at
io
ns
:A
D
A
lz
he
im
er
’s
di
se
as
e,
m
ild
co
gn
iti
ve
im
pa
irm
en
t
[3
13
],
CS
F
ce
re
br
os
pi
na
lf
lu
id
,A
β4
2
am
yl
oi
d-
β
1–
42
,p
-t
au
Ph
os
ph
or
yl
at
ed
ta
u,
t-
ta
u
to
ta
lt
au
,I
S
in
te
rn
al
st
an
da
rd
,e
nz
ym
e-
lin
ke
d
im
m
un
os
or
be
nt
as
sa
y
[2
28
],
U
PL
C/
TQ
-S
M
S
Ta
nd
em
Q
ua
dr
up
ol
e
M
as
s
Sp
ec
tr
om
et
ry
,N
C
no
nc
ar
rie
rs
,M
C
m
ut
at
io
n
ca
rr
ie
rs
,A
D
A
D
au
to
so
m
al
do
m
in
an
t
A
D
,N
R
no
t
re
po
rt
ed
,P
SE
N
pr
es
en
ili
n,
A
PP
am
yl
oi
d
pr
ec
ur
so
r
pr
ot
ei
n,
Pr
eA
D
Pr
ec
lin
ic
al
A
D
,D
SM
D
ia
gn
os
tic
an
d
St
at
is
tic
al
M
an
ua
lo
fM
en
ta
lD
is
or
de
rs
,N
IA
-A
A
N
at
io
na
lI
ns
tit
ut
e
on
A
gi
ng
–A
lz
he
im
er
’s
A
ss
oc
ia
tio
n,
N
IN
CD
S-
AD
RD
A
N
at
io
na
lI
ns
tit
ut
e
of
N
eu
ro
lo
gi
ca
l
an
d
Co
m
m
un
ic
at
iv
e
D
is
or
de
rs
an
d
St
ro
ke
an
d
th
e
A
lz
he
im
er
’s
D
is
ea
se
an
d
Re
la
te
d
D
is
or
de
rs
A
ss
oc
ia
tio
n,
IW
G
2
In
te
rn
at
io
na
lW
or
ki
ng
G
ro
up
,C
D
R
cl
in
ic
al
de
m
en
tia
ra
tin
g,
M
M
SE
m
in
i-m
en
ta
ls
ta
te
ex
am
in
at
io
n,
M
RI
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g,
co
m
pu
te
d
to
m
og
ra
ph
y,
D
om
in
an
tly
In
he
rit
ed
A
lz
he
im
er
N
et
w
or
k
[2
68
]
a T
he
‘A
D
C
SF
pr
of
ile
’c
on
si
st
s
of
hi
gh
t-
ta
u
an
d
p-
ta
u,
an
d
lo
w
A
β4
2
le
ve
ls
in
C
SF
;c
ut
-o
ff
va
lu
es
ar
e
sp
ec
ifi
ed
fo
r
ea
ch
st
ud
y.
U
nd
er
m
ai
n
fin
di
ng
,t
he
re
su
lts
ar
e
pr
es
en
te
d
as
si
gn
ifi
ca
nt
ly
el
ev
at
ed
(↑
),
si
gn
ifi
ca
nt
ly
re
du
ce
d
(↓
),
or
no
n-
si
gn
ifi
ca
nt
di
ff
er
en
ce
s
(↔
)
in
sT
RE
M
2
Jay et al. Molecular Neurodegeneration  (2017) 12:56 Page 23 of 33
studies that did divide subjects by stage of disease progres-
sion, CSF sTREM2 levels were found to be significantly
higher in patients with AD-related mild cognitive impair-
ment [202, 315, 316] and mild dementia [202, 225]
compared to controls and AD cases [202]. Cross-sectional
studies in patients with dominantly inherited AD con-
firmed a significant increase in CSF sTREM2 starting
5 years before expected onset of clinical dementia, but
found no significant differences between AD patients and
controls beyond 5 years after symptom onset [12].
Together, these studies suggest a specific elevation in CSF
sTREM2 levels in the early symptomatic stages of AD.
Interestingly, sTREM2 was also found to be significantly
elevated specifically in early stages of ALS pathology
before returning to baseline at late stages of disease [317].
While it’s not clear whether these disease-stage
dependent effects are due to a common mechanism, it
will be interesting to see whether this pattern continues
to be consistent across NDDs.
The detection and reported changes with disease pro-
gression in CSF levels of sTREM2 have raised questions
of its origin and biological meaning in health and dis-
ease. In AD patients, CSF sTREM2 was not associated
with changes in CSF Aβ42 [86, 202, 314, 316] but posi-
tively correlated with CSF biomarkers total tau [86, 202]
and phosphorylated tau [202, 314, 316], including in
cross-sectional cohorts with dominantly inherited AD
[202]. Several groups have proposed that CSF sTREM2
levels may signify microglial activation in response to
AD-related pathology [86, 202, 313, 314, 316]. Evidence
of CSF sTREM2 positively correlating with glial protein
YKL-40 in CSF [314, 316], another proposed AD immune
biomarker, in addition to immunosuppressive agents caus-
ing a reduction in CSF sTREM2 levels [313] are consistent
with this theory. Changes in sTREM2 appear to be inde-
pendent of ApoE4 status [318–320]. Further work asses-
sing how sTREM2 generation changes with microglial
phenotype will be needed to definitively validate sTREM2
as an indicator of microglial activation. A recent clinical
study proposes a neuroprotective role for sTREM2,
reporting higher gray matter volume in areas susceptible
to AD pathology for mild cognitive impairment (MCI)
and AD patients with high CSF sTREM2 levels [316]
though this correlation was not found in all studies.
Higher levels of CSF sTREM2 at late stages of ALS also
correlated with longer survival [317]. These findings, in
combination with the positive correlation between CSF
tau and sTREM2, could indicate that elevated sTREM2
production occurs as a protective response to neurode-
generation, though there is no definitive consensus yet as
to the biological significance of sTREM2.
The current data on sTREM2 illustrate limitations for
its use as an NDD biomarker. Several NDDs including
MS, AD and FTD, are associated with elevated sTREM2
in CSF [86, 314], suggestive of a common innate
immune mechanism in these distinct pathologies. It has
also been suggested as a biomarker for welding fume
exposure [142] and, as discussed above, can be regulated
in many other inflammation-related contexts. This lack
of disease and context specificity in sTREM2 changes
raises concerns for its utility as a diagnostic tool for AD.
Recent data show CSF sTREM2 levels are altered differ-
entially throughout AD progression. These observations
raise questions about its utility as a diagnostic readout
for AD disease status in diverse neurologic cohorts,
though does suggest that sTREM2 levels could be help-
ful in identifying stage of AD in coordination with other
biomarkers [321]. Moreover, Heslegrave and colleagues
[314] acknowledged that sTREM2 levels in AD patients
and controls, while significantly different, substantially
overlap, thereby further limiting its diagnostic utility.
Transcriptome-based studies found dysregulation of sev-
eral innate immune genes in blood from AD patients
[320], which led others to assess whether TREM2
expression might also be changed in blood. While stud-
ies did find a correlation between TREM2 expression on
blood monocytes and an AD diagnosis [128], sTREM2
in plasma was shown to not correlate with CSF sTREM2
levels [86] and plasma samples yielded non-significant
differences in sTREM2 of AD and FTD patients com-
pared to healthy controls [86, 225]. While sTREM2
alone does have clear limitations as a biomarker, it may
have a potential application as part of a biomarker panel
to assess the immune response in AD and other neuro-
degenerative diseases.
TREM2-directed therapeutics
In addition to its potential as a biomarker, many have
suggested that TREM2-directed therapeutics may prove
to be a novel target for NDDs. There are several factors
to consider in developing TREM2 therapeutics. First,
while TREM2 variants confer as strong a risk for devel-
oping AD as one copy of the ApoE4 allele, the minor
allele frequency of TREM2 variants are substantially
lower, with less than 1% for TREM2 to approximately
20% for ApoE4 [7, 55]. Thus, though some have sug-
gested that therapeutics might want to restore WT
TREM2 function in these variant carriers as a potential
therapeutic, correcting TREM2 variants are not likely to
be a broadly applicable therapeutic approach. Rather,
studying TREM2 variants that confer risk for NDDs will
illuminate components of the immune response cen-
trally important in immune modulation of pathology,
and serve as a prerequisite to developing targeted
immune-directed therapeutics. So far, the field has iden-
tified potential changing roles for immune cell function
throughout progression of AD, and possibly identified a
key role for peripherally derived immune cells in AD
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pathology, which would greatly aid in therapeutically
targeting the immune cells relevant to AD pathology.
Common functions of TREM2 have been identified
across multiple NDDs which suggest therapeutic targets
could be relevant to multiple disease contexts. However, we
have not found a simple explanation for what TREM2 does
across cell types and contexts. Based on its disease progres-
sion dependent effects, it does not appear that simply
activating or inhibiting TREM2 would be beneficial even in
the context of AD. There may also be sex-dependent effects
of TREM2, as some [86] but not all [202] have shown
differences in sTREM2 levels in CSF between male and
female subjects. Likewise, a TREM2 variant was associated
with markers of systemic inflammation specifically in
women not men, and was hormone-independent [110].
With the lack of strong biomarkers to stage NDDs and the
variability in clinical progression among patients, it is not
likely that increasing or decreasing TREM2 will be the
universal solution to NDD pathologies.
Conclusion
Rather, understanding when, where and how TREM2 is
working is more likely to provide insights into immune
function that can be modulated throughout disease pro-
gression. However, the emphasis on understanding
TREM2 in NDDs began just 4 years ago and we still have
a long way to go to understand TREM2’s expression, sig-
naling, function and effects on these various pathologies.
It will also be essential to start to dissect how the diverse
array of TREM2 variants result in NDD risk. While this
understanding of TREM2 variants may not directly trans-
late into TREM2-directed biomarkers or therapeutics at
this time, the insight into how the immune system actively
participates in NDD pathology promises to provide many
avenues for a new class of immune-directed therapeutic
targets for NDDs.
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